_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
502912758,7/14/2014 12:48:35,,1322813721,7/14/2014 12:48:27,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],"protocol,",eda,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 12:50:57,,1322815401,7/14/2014 12:50:37,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],"with a new treatment protocol,",n/a,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 13:10:14,,1322828356,7/14/2014 13:09:25,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],induced with,N/A,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 13:26:16,,1322839301,7/14/2014 13:25:49,prodege,1,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],"with a new treatment protocol, which combined",N/A,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 13:31:29,,1322842708,7/14/2014 13:29:53,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,[OTHER],[OTHER],complication,N/A,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 13:35:17,,1322845512,7/14/2014 13:34:34,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],treatment with,N/A,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 13:43:49,,1322851795,7/14/2014 13:43:10,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],"HEMOPHILIA FACTOR VIII,",n/a,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 13:53:56,,1322859194,7/14/2014 13:51:27,neodev,1,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],successfully induced immune tolerance in,N/A,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 13:55:50,,1322860542,7/14/2014 13:53:49,clixsense,1,8100278,USA,FL,Orlando,98.70.77.97,[TREATS],[TREATS],"treatment of patients with HEMOPHILIA A with new treatment protocol, which combined FACTOR VIII, and IgG,",N/A,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 13:57:49,,1322861832,7/14/2014 13:57:34,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,[OTHER],[OTHER],combined,Na,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 14:01:21,,1322864360,7/14/2014 14:00:16,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,[PREVENTS],[PREVENTS],"HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII,",N/A,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 14:09:10,,1322869459,7/14/2014 14:08:36,instagc,1,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],treatment of patients,N/A,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 14:14:57,,1322873420,7/14/2014 14:14:30,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],is a serious complication of the treatment of patients with,N/A,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 14:18:56,,1322876011,7/14/2014 14:18:44,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],complication,N/A,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912758,7/14/2014 14:34:31,,1322887184,7/14/2014 14:34:25,instagc,1,27753923,GBR,"","",188.30.192.65,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],factor VIII.,n/a,105,238,116,249,1,RO-may_treat,908360-FS1,"The development of antibodies to factor VIII is a serious complication of the treatment of patients with HEMOPHILIA A We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined FACTOR VIII, cyclophosphamide, and high dose intravenous IgG, followed by regular prophylactic treatment with factor VIII.",HEMOPHILIA A,FACTOR VIII
502912759,7/14/2014 12:44:02,,1322810733,7/14/2014 12:43:02,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,they are all symptoms,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 12:45:29,,1322811733,7/14/2014 12:45:21,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],syndrome,da,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 12:57:27,,1322819749,7/14/2014 12:57:05,prodege,1,11616695,GBR,P7,Wigan,92.29.199.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],by the triad,N/A,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 12:58:24,,1322820444,7/14/2014 12:57:50,clixsense,1,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],triad of,n/a,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 13:00:35,,1322821887,7/14/2014 12:59:46,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],by the triad of,N/A,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 13:00:43,,1322821954,7/14/2014 13:00:07,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],characterized by,N/A,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 13:00:42,,1322821957,7/14/2014 12:59:36,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[PART_OF],[PART_OF],The hemolytic uremic syndrome characterized by triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA,n/a,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 13:05:33,,1322824984,7/14/2014 13:04:50,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[IS_A],[IS_A],MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA,na,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 13:15:45,,1322832067,7/14/2014 13:15:15,zoombucks,1,5919735,USA,PA,Doylestown,173.49.91.231,[PART_OF],[PART_OF],MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA,N/A,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 13:24:30,,1322838134,7/14/2014 13:23:27,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized by,N/A,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 13:32:56,,1322843874,7/14/2014 13:31:30,elite,1,27433978,AUS,05,Plympton,110.174.120.88,[ASSOCIATED_WITH],[ASSOCIATED_WITH],syndrome is characterized by the triad of,N/A,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 13:55:41,,1322860490,7/14/2014 13:54:58,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[IS_A],[IS_A],MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA,N/A,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 13:59:39,,1322863122,7/14/2014 13:59:15,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],characterized,Na,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 14:08:05,,1322868860,7/14/2014 14:07:22,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],triad of,N/A,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912759,7/14/2014 14:10:20,,1322870108,7/14/2014 14:10:03,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA,N/A,97,63,112,96,-1,RO-has_manifestation,906262-FS1,The hemolytic uremic syndrome is characterized by the triad of MICROANGIOPATHIC HEMOLYTIC ANEMIA THROMBOCYTOPENIA and acute renal failure.,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
502912760,7/14/2014 12:51:03,,1322815441,7/14/2014 12:50:27,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[IS_A],[IS_A],including,N/A,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 13:02:54,,1322823364,7/14/2014 13:02:29,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],including,N/A,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 13:05:00,,1322824664,7/14/2014 13:04:34,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],have become,N/A,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 13:07:03,,1322826049,7/14/2014 13:06:33,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[MANIFESTATION],[MANIFESTATION],"have become apparent,",n/a,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 13:19:33,,1322834562,7/14/2014 13:19:04,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PART_OF],[PART_OF],including,N/A,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 13:29:40,,1322841566,7/14/2014 13:27:52,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]","follow, NUTRITIONAL DEFICIENCIES PROTEIN CALORIE MALNUTRITION deficiencies",N/A,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 13:51:20,,1322857404,7/14/2014 13:50:51,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"become apparent, including",n/a,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 13:58:31,,1322862281,7/14/2014 13:58:13,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],"apparent,",Na,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 14:11:50,,1322871190,7/14/2014 14:11:25,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[PREVENTS],[PREVENTS],NUTRITIONAL DEFICIENCIES PROTEIN CALORIE MALNUTRITION,N/A,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 14:15:27,,1322873748,7/14/2014 14:15:19,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],become,N/A,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 14:21:44,,1322878039,7/14/2014 14:21:24,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],including,N/A,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 14:36:07,,1322888355,7/14/2014 14:35:59,instagc,1.0,27753923,GBR,"","",188.30.192.65,[PREVENTS],[PREVENTS],PROTEIN CALORIE MALNUTRITION,n/a,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 14:40:52,,1322891637,7/14/2014 14:40:19,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[CAUSES],[CAUSES],NUTRITIONAL DEFICIENCIES PROTEIN CALORIE MALNUTRITION,n/a,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 14:46:49,,1322895558,7/14/2014 14:46:26,elite,1,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]","have become apparent,",[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912760,7/14/2014 14:54:33,,1322900048,7/14/2014 14:54:09,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],including,N/A,194,137,221,161,-1,RO-cause_of,900160-FS1,"Unfortunately the nutritional adequacy of the postoperative diet has frequently been overlooked, and in the months to years that follow, NUTRITIONAL DEFICIENCIES have become apparent, including PROTEIN CALORIE MALNUTRITION and various vitamin and mineral deficiencies contributing to medical illnesses and limiting optimal health.",PROTEIN CALORIE MALNUTRITION,NUTRITIONAL DEFICIENCIES
502912761,7/14/2014 12:48:57,,1322813966,7/14/2014 12:48:46,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],pathogenetic,da,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 12:54:23,,1322817848,7/14/2014 12:53:23,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],development of,n/a,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 12:55:24,,1322818449,7/14/2014 12:54:45,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[CAUSES],[CAUSES],development of ALLERGY of the immediate type,n/a,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 12:55:31,,1322818514,7/14/2014 12:54:47,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[MANIFESTATION],[MANIFESTATION],in the development of,n/a,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 12:56:43,,1322819311,7/14/2014 12:56:20,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[MANIFESTATION],[MANIFESTATION],of the immediate type,N/A,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 13:01:54,,1322822714,7/14/2014 13:01:33,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],of the immediate type,N/A,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 13:04:33,,1322824405,7/14/2014 13:03:46,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],development,N/A,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 13:32:30,,1322843507,7/14/2014 13:31:42,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],of the immediate type,N/A,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 13:36:16,,1322846275,7/14/2014 13:35:42,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of type,N/A,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 13:36:26,,1322846427,7/14/2014 13:35:40,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],of the immediate type,N/A,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 13:39:26,,1322848610,7/14/2014 13:37:43,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[MANIFESTATION],[MANIFESTATION],development of ALLERGY of the immediate type HYPERSENSITIVITY,N/A,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 14:05:13,,1322866910,7/14/2014 14:03:55,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[CAUSES] [LOCATION],"[CAUSES]
[LOCATION]",development ALLERGY of the immediate type HYPERSENSITIVITY,N/A,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 14:12:05,,1322871433,7/14/2014 14:11:51,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[SYMPTOM],[SYMPTOM],ALLERGY HYPERSENSITIVITY,N/A,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 14:16:37,,1322874506,7/14/2014 14:16:22,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],role,N/A,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912761,7/14/2014 14:19:20,,1322876346,7/14/2014 14:18:00,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],of the immediate type,N/A,94,124,100,140,-1,RO-cause_of,900083-FS1,These data support the hypothesis concerning a pathogenetic role of IFN in the development of ALLERGY of the immediate type HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY
502912762,7/14/2014 12:49:15,,1322814161,7/14/2014 12:48:14,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[OTHER],[OTHER],there could be a,N/A,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 12:49:24,,1322814297,7/14/2014 12:48:29,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],whether there could be,n/a,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 13:03:45,,1322823980,7/14/2014 13:01:47,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],reactivity investigated,N/A,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 13:08:50,,1322827317,7/14/2014 13:07:38,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CAUSES],[CAUSES],there could be,na,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 13:21:53,,1322836234,7/14/2014 13:21:25,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,N/A,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 13:31:29,,1322842740,7/14/2014 13:28:27,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",investigated,N/A,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 13:44:39,,1322852393,7/14/2014 13:43:54,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],could be,n/a,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 13:51:46,,1322857713,7/14/2014 13:49:46,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],To understand altered airway reactivity in the MECONIUM ASPIRATION SYNDROME study investigated MECONIUM DOSE DEPENDENT RESPONSE,N/A,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 13:56:45,,1322861138,7/14/2014 13:56:14,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MECONIUM ASPIRATION SYNDROME MECONIUM DOSE DEPENDENT RESPONSE,n/a,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 14:05:34,,1322867133,7/14/2014 14:04:36,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",could be a tracheal smooth muscle,na,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 14:06:23,,1322867742,7/14/2014 14:06:01,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],MECONIUM ASPIRATION SYNDROME MECONIUM DOSE DEPENDENT RESPONSE,N/A,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 14:27:03,,1322881861,7/14/2014 14:25:25,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],reactivity SYNDROME RESPONSE,N/A,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 14:32:15,,1322885780,7/14/2014 14:32:08,instagc,1.0,27753923,GBR,"","",188.30.192.65,[SYMPTOM],[SYMPTOM],DOSE DEPENDENT,n/a,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 14:39:31,,1322890668,7/14/2014 14:37:11,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in this study we investigated whether there could be a,N/A,169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912762,7/14/2014 14:44:07,,1322893845,7/14/2014 14:43:47,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],there could be,[CAUSES],169,85,200,113,1,RO-has_causative_agent,903672-FS1,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
502912763,7/14/2014 12:48:00,,1322813294,7/14/2014 12:47:53,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],bacteroid,da,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 12:49:38,,1322814424,7/14/2014 12:49:16,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[CAUSES],[CAUSES],bacterial vaginosis,N/A,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 12:52:18,,1322816369,7/14/2014 12:51:47,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,this sentence makes absolutely no sense,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 13:01:10,,1322822206,7/14/2014 13:00:36,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],BACTERIA BACTERIAL,N/A,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 13:01:59,,1322822794,7/14/2014 13:00:49,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[NONE],[NONE],n/a,This is a alphabetical list of things that dont seem related,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 13:11:45,,1322829354,7/14/2014 13:10:16,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],effect,N/A,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 13:33:38,,1322844379,7/14/2014 13:32:08,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],bacteria,N/A,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 13:38:57,,1322848269,7/14/2014 13:38:24,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[NONE],[NONE],N/A,Its just an alphabetical list of words,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 13:42:58,,1322851204,7/14/2014 13:41:59,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BACTERIA bacteria bacteria bacterial vaginosis BACTERIAL VAGINOSIS,N/A,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 13:43:05,,1322851331,7/14/2014 13:42:33,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BACTERIA BACTERIAL VAGINOSIS,n/a,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 13:51:04,,1322857217,7/14/2014 13:49:33,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[NONE],[NONE],N/A,THE SENTENCE LISTS ONLY ALL NAMES OF BACTERIA,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 13:56:54,,1322861231,7/14/2014 13:56:21,superrewards,1.0,22551185,GBR,"","",87.113.87.199,[NONE],[NONE],N/A,Just a long alphabetical list.,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 14:02:11,,1322864932,7/14/2014 14:01:39,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",baculovirus,na,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 14:04:16,,1322866321,7/14/2014 14:03:13,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[OTHER],[OTHER],bacteremia bacteremia bacteria BACTERIA bacteria bacteria bacterial vaginosis BACTERIAL VAGINOSIS bactericidal bacteriocin bacteriogenic,n/a,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912763,7/14/2014 14:14:01,,1322872807,7/14/2014 14:13:53,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],bacteriogenic,N/A,404,457,411,476,-1,RO-has_causative_agent,903751-FS1,"? glucuronidase  ? glucuronidase   Babbitt metal  Babbitt metal   Babcock's operation  Babcock's operation   Babesia  Babesia   babesiosis  babesiosis   Babinski's reflex  Babinski's reflex   bacciform  bacciform   Bacillaceae  Bacillaceae   bacillar  bacitracin  bacitracin   backache  backache   backbone  backbone   backcross  backcross   backscatter  backscatter   bacteremia  bacteremia   bacteria  BACTERIA   bacteria  bacteria   bacterial vaginosis  BACTERIAL VAGINOSIS   bactericidal  bacteriocin   bacteriogenic  bacteriogenic   bacteriohemagglutinin  bacteriohemagglutinin   bacteriohemolysin  bacteriohemolysin   bacteriologic  bacteriologic   bacteriologist  bacteriophytoma   bacterioprecipitin  bacterioprecipitin   bacterioprotein  bacterioprotein   bacteriopsonin  bacteriopsonin   bacteriosis  bacteriosis   bacteriostasis  bacteriostasis   bacteriuria   bacteroid  bacteroid   Bacteroides  Bacteroides   baculovirus  baculovirus   baffle  baffle   bagassosis  bagassosis   Bailey, Harriet  Bailey, Harriet   Bainbridge effect  Bainbridge effect   balanopreputial  balanopreputial   balanorrhagia  balanorrhagia   balantidial  balantidial   balantidiasis  balantidiasis.",BACTERIA,BACTERIAL VAGINOSIS
502912764,7/14/2014 12:54:46,,1322818063,7/14/2014 12:54:02,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],symptoms associated with,n/a,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 12:56:57,,1322819485,7/14/2014 12:56:32,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS,n/a,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 13:01:47,,1322822663,7/14/2014 13:01:19,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 13:08:16,,1322826997,7/14/2014 13:06:09,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[SYMPTOM],[SYMPTOM],ocular symptoms associated with,N/A,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 13:09:50,,1322828038,7/14/2014 13:09:25,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[SYMPTOM],[SYMPTOM],symptoms associated with,N/A,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 13:20:30,,1322835191,7/14/2014 13:19:55,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],such as seasonal and,N/A,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 13:23:27,,1322837509,7/14/2014 13:22:02,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",OCULAR ALLERGY CONDITIONS and PERENNIAL CONJUNCTIVITIS affect allergy sufferer,N/A,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 13:26:01,,1322839161,7/14/2014 13:25:44,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PART_OF],[PART_OF],such as,N/A,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 13:48:31,,1322855352,7/14/2014 13:47:54,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",OCULAR ALLERGY CONDITIONS PERENNIAL ALLERGIC CONJUNCTIVITIS,n/a,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 13:57:49,,1322861839,7/14/2014 13:57:12,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",seasonal,na,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 13:58:09,,1322861978,7/14/2014 13:57:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],common such seasonal,Na,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 13:58:58,,1322862620,7/14/2014 13:58:34,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],symptoms associated with,n/a,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 14:09:32,,1322869652,7/14/2014 14:09:11,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],such as,N/A,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 14:22:56,,1322878846,7/14/2014 14:22:29,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],such as seasonal and,N/A,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912764,7/14/2014 14:33:40,,1322886698,7/14/2014 14:33:33,instagc,1.0,27753923,GBR,"","",188.30.192.65,[MANIFESTATION],[MANIFESTATION],twice as,n/a,99,52,131,77,1,RO-cause_of,900088-FS1,The ocular symptoms associated with the most common OCULAR ALLERGY CONDITIONS such as seasonal and PERENNIAL ALLERGIC CONJUNCTIVITIS are twice as likely to affect the allergy sufferer rather than nasal symptoms alone.,PERENNIAL ALLERGIC CONJUNCTIVITIS,OCULAR ALLERGY CONDITIONS
502912765,7/14/2014 12:47:06,,1322812732,7/14/2014 12:46:58,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],detected,da,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 13:02:12,,1322822902,7/14/2014 13:01:39,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[OTHER],[OTHER],were detected in all teeth,Teeth can get plaque.,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 13:02:23,,1322823024,7/14/2014 13:02:03,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM] [SIDE_EFFECT],"[SYMPTOM]
[SIDE_EFFECT]",detected,n/a,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 13:02:23,,1322823026,7/14/2014 13:02:01,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"under investigation,",n/a,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 13:08:14,,1322826959,7/14/2014 13:07:38,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],were detected in all,N/A,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 13:34:28,,1322845024,7/14/2014 13:33:52,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[OTHER],[OTHER],detected in,N/A,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 13:40:45,,1322849623,7/14/2014 13:39:22,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"DENTAL PLAQUES were detected in teeth investigation,",N/A,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 13:44:23,,1322852254,7/14/2014 13:43:35,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[OTHER],[OTHER],DENTAL PLAQUES were detected in all the teeth,N/A,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 13:54:42,,1322859774,7/14/2014 13:54:11,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],detected in,na,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 14:02:35,,1322865195,7/14/2014 14:01:56,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[LOCATION],[LOCATION],"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",N/A,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 14:08:35,,1322869146,7/14/2014 14:08:06,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],in all the teeth,N/A,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 14:10:05,,1322869970,7/14/2014 14:09:17,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],were detected in all the teeth,N/A,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 14:34:39,,1322887315,7/14/2014 14:34:33,instagc,1.0,27753923,GBR,"","",188.30.192.65,[LOCATION],[LOCATION],teeth,n/a,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 14:37:52,,1322889540,7/14/2014 14:37:28,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[SYMPTOM],[SYMPTOM],DENTAL PLAQUES TEETH.,n/a,98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912765,7/14/2014 14:40:51,,1322891617,7/14/2014 14:40:31,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[LOCATION],[LOCATION],were detected,[LOCATION],98,0,102,14,1,RO-has_finding_site,905216-FS1,"DENTAL PLAQUES were detected in all the teeth under investigation, with the exception of impacted TEETH.",TEETH,DENTAL PLAQUES
502912766,7/14/2014 12:55:34,,1322818543,7/14/2014 12:54:49,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],often seen in specimens from,n/a,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 13:06:07,,1322825439,7/14/2014 13:04:31,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[ASSOCIATED_WITH],[ASSOCIATED_WITH],who had a personal or family history of,N/A,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 13:16:07,,1322832320,7/14/2014 13:15:45,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],seen,N/A,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 13:22:05,,1322836399,7/14/2014 13:21:36,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],but was absent in specimens from those patients with,N/A,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 13:34:20,,1322844893,7/14/2014 13:32:10,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[CONTRAINDICATES],[CONTRAINDICATES],MBP deposition was seen in specimens with atopic dermatitis who had a personal or family history RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS,N/A,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 13:35:33,,1322845772,7/14/2014 13:34:46,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[OTHER],[OTHER],absent in specimens from those patients with,na,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 13:42:28,,1322850829,7/14/2014 13:41:46,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RESPIRATORY ATOPY ATOPIC DERMATITIS,n/a,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 13:42:45,,1322851005,7/14/2014 13:41:26,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],but was absent in specimens,N/A,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 14:04:03,,1322866178,7/14/2014 14:03:18,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],those patients with family history of respiratory atopy.,na,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 14:08:04,,1322868848,7/14/2014 14:07:32,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],RESPIRATORY ATOPY ATOPIC DERMATITIS,N/A,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 14:14:20,,1322872918,7/14/2014 14:14:11,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],from,N/A,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 14:28:03,,1322882600,7/14/2014 14:27:04,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],often seen,N/A,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 14:30:58,,1322884821,7/14/2014 14:30:00,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],but was absent in specimens from those patients with,N/A,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 14:35:41,,1322888030,7/14/2014 14:35:33,instagc,1.0,27753923,GBR,"","",188.30.192.65,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",ATOPIC,n/a,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912766,7/14/2014 14:38:53,,1322890277,7/14/2014 14:38:25,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",RESPIRATORY ATOPY ATOPIC DERMATITIS,n/a,200,129,216,146,-1,RO-cause_of,900443-FS1,A strong MBP deposition was often seen in specimens from patients with atopic dermatitis who had a personal or family history of RESPIRATORY ATOPY but was absent in specimens from those patients with ATOPIC DERMATITIS who had neither a personal nor a family history of respiratory atopy.,ATOPIC DERMATITIS,RESPIRATORY ATOPY
502912767,7/14/2014 12:48:08,,1322813408,7/14/2014 12:48:01,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[SYMPTOM],[SYMPTOM],the,da,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 12:50:10,,1322814802,7/14/2014 12:49:39,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[IS_A],[IS_A],features consistent with a NEURALGIA,N/A,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 12:52:49,,1322816698,7/14/2014 12:52:19,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],features consistent with,n/a,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 13:04:04,,1322824155,7/14/2014 13:03:41,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[PART_OF],[PART_OF],has features consistent with a,N/A,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 13:07:57,,1322826780,7/14/2014 13:07:34,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],has features consistent with,n/a,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 13:29:25,,1322841391,7/14/2014 13:28:51,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],features consistent with a,N/A,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 13:33:46,,1322844446,7/14/2014 13:32:45,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],consistent with a,na,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 13:45:08,,1322852630,7/14/2014 13:44:34,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],PAIN NEURALGIA,n/a,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 13:50:05,,1322856413,7/14/2014 13:49:39,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PAIN NEURALGIA,n/a,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 13:55:54,,1322860577,7/14/2014 13:54:58,superrewards,1.0,22551185,GBR,"","",87.113.87.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has features consistent with,N/A,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 14:16:01,,1322874148,7/14/2014 14:15:27,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],cause,na,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 14:17:10,,1322874872,7/14/2014 14:17:01,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"musculature,",N/A,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 14:25:24,,1322880696,7/14/2014 14:24:55,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],has features consistent with,N/A,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 14:36:23,,1322888549,7/14/2014 14:36:15,instagc,1.0,27753923,GBR,"","",188.30.192.65,[TREATS],[TREATS],damage pelvic,n/a,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912767,7/14/2014 14:47:04,,1322895684,7/14/2014 14:46:41,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[CAUSES],[CAUSES],PAIN NEURALGIA,n/a,102,138,105,147,-1,RO-has_definitional_manifestation,904803-FS1,"There is a high incidence of sciatica and of damage to the pelvic floor musculature, but although the PAIN has features consistent with a NEURALGIA its cause is unknown.",PAIN,NEURALGIA
502912768,7/14/2014 12:46:03,,1322812031,7/14/2014 12:45:56,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ERYTHEMATOSUS,da,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 12:51:25,,1322815694,7/14/2014 12:51:04,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[IS_A],[IS_A],subset,N/A,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 12:54:44,,1322818051,7/14/2014 12:54:26,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],is a subset of,n/a,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 13:05:28,,1322824948,7/14/2014 13:05:00,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],characterized by,N/A,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 13:22:31,,1322836742,7/14/2014 13:22:07,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],is a subset of,N/A,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 13:25:10,,1322838531,7/14/2014 13:24:54,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PART_OF],[PART_OF],subset,N/A,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 13:31:55,,1322843011,7/14/2014 13:30:33,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],subset of,na,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 13:34:43,,1322845194,7/14/2014 13:34:07,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],is a subset of,N/A,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 13:35:41,,1322845841,7/14/2014 13:35:14,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[IS_A],[IS_A],subset,N/A,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 13:37:15,,1322847031,7/14/2014 13:36:56,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],is a subset of,N/A,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 13:46:12,,1322853535,7/14/2014 13:45:11,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],subset of,n/a,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 13:49:18,,1322855988,7/14/2014 13:48:37,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) LUPUS ERYTHEMATOSUS,n/a,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 13:49:31,,1322856131,7/14/2014 13:48:10,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",is a subset of,N/A,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 13:56:55,,1322861246,7/14/2014 13:56:41,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],subset,Na,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912768,7/14/2014 14:01:55,,1322864728,7/14/2014 14:01:22,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS,N/A,0,19,37,38,-1,RO-cause_of,900009-FS1,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) is a subset of LUPUS ERYTHEMATOSUS which is characterized by unique cutaneous manifestations and immunological abnormalities.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS
502912769,7/14/2014 12:45:37,,1322811794,7/14/2014 12:45:30,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],CAUSES,da,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 12:47:02,,1322812654,7/14/2014 12:46:40,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],which may be the first manifestation,n/a,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 12:58:33,,1322820587,7/14/2014 12:58:18,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[MANIFESTATION],[MANIFESTATION],manifestation,N/A,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 13:04:35,,1322824425,7/14/2014 13:04:17,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[MANIFESTATION],[MANIFESTATION],be the first manifestation of,n/a,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 13:17:12,,1322833087,7/14/2014 13:16:56,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],manifestation,N/A,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 13:18:22,,1322833805,7/14/2014 13:17:16,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[MANIFESTATION],[MANIFESTATION],manifestation of,N/A,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 13:40:41,,1322849562,7/14/2014 13:40:02,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[MANIFESTATION],[MANIFESTATION],TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS HEPATOCELLULAR CARCINOMA,n/a,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 14:00:15,,1322863474,7/14/2014 13:59:39,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA,N/A,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 14:15:46,,1322873979,7/14/2014 14:15:37,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CAUSES,N/A,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 14:24:26,,1322879871,7/14/2014 14:23:58,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],which may be the first manifestation of,N/A,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 14:28:55,,1322883286,7/14/2014 14:28:32,instagc,1.0,13763729,USA,"","",75.182.89.225,[MANIFESTATION],[MANIFESTATION],the first manifestation,N/A,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 14:35:22,,1322887874,7/14/2014 14:35:14,instagc,1.0,27753923,GBR,"","",188.30.192.65,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],BLOODY ASCITES,n/a,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 14:39:44,,1322890856,7/14/2014 14:39:17,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[MANIFESTATION],[MANIFESTATION],manifestation,[MANIFESTATION],32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 14:45:04,,1322894424,7/14/2014 14:44:41,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[MANIFESTATION],[MANIFESTATION],TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS HEPATOCELLULAR CARCINOMA,n/a,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912769,7/14/2014 14:54:54,,1322900292,7/14/2014 14:54:35,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],manifestation of,N/A,32,121,79,145,1,RO-disease_may_have_finding,902829-FS1,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
502912770,7/14/2014 12:46:39,,1322812424,7/14/2014 12:46:00,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 12:47:35,,1322813058,7/14/2014 12:47:08,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[PART_OF],[PART_OF],with,N/A,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 13:03:45,,1322823952,7/14/2014 13:03:28,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH] [SIDE_EFFECT],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",with,n/a,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 13:05:21,,1322824860,7/14/2014 13:04:36,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PREVENTS],[PREVENTS],significant results,n/a,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 13:07:37,,1322826497,7/14/2014 13:06:56,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 13:13:31,,1322830593,7/14/2014 13:12:36,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS] [PART_OF] [IS_A],"[TREATS]
[IS_A]
[PART_OF]",are,N/A,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 13:16:07,,1322832331,7/14/2014 13:15:30,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,na,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 13:17:53,,1322833518,7/14/2014 13:17:34,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 13:41:25,,1322850052,7/14/2014 13:40:56,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 13:53:54,,1322859176,7/14/2014 13:52:24,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[OTHER],[OTHER],lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,n/a,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 13:54:10,,1322859413,7/14/2014 13:53:37,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[PREVENTS],[PREVENTS],lack of,na,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 13:56:21,,1322860888,7/14/2014 13:55:59,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],with,Na,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 14:01:35,,1322864521,7/14/2014 13:59:52,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[CAUSES] [PREVENTS],"[PREVENTS]
[CAUSES]",lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,N/A,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 14:07:20,,1322868375,7/14/2014 14:06:54,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],lack of DEHYDRATION with,N/A,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912770,7/14/2014 14:11:24,,1322870906,7/14/2014 14:11:07,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],DEHYDRATION INCREASING TEMPERATURE SALT ADDITION.,N/A,106,123,116,163,1,RO-may_prevent,907161-FS1,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
502912771,7/14/2014 12:52:18,,1322816366,7/14/2014 12:51:26,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[OTHER],[OTHER],potential contribution,N/A,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 12:54:25,,1322817860,7/14/2014 12:52:49,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],and their potential contribution to etiology,n/a,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 13:02:28,,1322823057,7/14/2014 13:01:56,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],and their potential contribution to the etiology of,N/A,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 13:13:36,,1322830625,7/14/2014 13:12:16,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[LOCATION],[LOCATION],contribution to the etiology,N/A,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 13:17:30,,1322833270,7/14/2014 13:17:01,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],developing,N/A,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 13:23:55,,1322837737,7/14/2014 13:23:35,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[LOCATION],[LOCATION],in,N/A,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 13:30:46,,1322842332,7/14/2014 13:29:30,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and their potential contribution to,N/A,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 14:21:27,,1322877813,7/14/2014 14:20:54,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES] [SYMPTOM] [MANIFESTATION],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]",potential contribution,na,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 14:35:32,,1322887965,7/14/2014 14:35:24,instagc,1.0,27753923,GBR,"","",188.30.192.65,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],NEUROLOGICAL DISEASES,n/a,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 14:40:16,,1322891222,7/14/2014 14:39:46,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NERVOUS SYSTEM NEUROLOGICAL DISEASES,n/a,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 14:42:31,,1322892729,7/14/2014 14:41:59,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],potential contribution to,[ASSOCIATED_WITH],102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 14:55:47,,1322900820,7/14/2014 14:54:55,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],of the function of,N/A,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 14:57:00,,1322901727,7/14/2014 14:56:46,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],etiology of,N/a,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 15:02:14,,1322904814,7/14/2014 15:01:33,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.26,[LOCATION],[LOCATION],SYSTEM NEUROLOGICAL,N/A,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912771,7/14/2014 15:03:04,,1322905308,7/14/2014 15:02:14,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],NERVOUS SYSTEM,n/a,102,169,115,190,1,RO-has_finding_site,905142-FS1,This review summarizes the current knowledge of the function of microRNAs in the developing and adult NERVOUS SYSTEM and their potential contribution to the etiology of NEUROLOGICAL DISEASES,NERVOUS SYSTEM,NEUROLOGICAL DISEASES
502912772,7/14/2014 12:59:10,,1322820971,7/14/2014 12:58:12,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],FOR ENDPOINT reduction randomised trial against,n/a,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 13:04:06,,1322824174,7/14/2014 13:03:46,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SIDE_EFFECT],[SIDE_EFFECT],reduction,Na,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 13:12:35,,1322829848,7/14/2014 13:11:46,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],reduction in,N/A,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 13:14:58,,1322831511,7/14/2014 13:13:37,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[PREVENTS],[PREVENTS],reduction,N/A,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 13:23:12,,1322837345,7/14/2014 13:22:32,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],the reduction in study a randomised trial,N/A,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 13:26:40,,1322839544,7/14/2014 13:26:08,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],reduction in,N/A,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 13:32:42,,1322843676,7/14/2014 13:31:57,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],reduction in,na,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 13:37:41,,1322847336,7/14/2014 13:36:27,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],reduction in,N/A,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 13:42:18,,1322850678,7/14/2014 13:41:46,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[TREATS],[TREATS],reduction in,N/A,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 13:57:22,,1322861529,7/14/2014 13:55:45,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[TREATS],[TREATS],reduction in,I Did not select none so why do i have to explain why?,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 13:59:34,,1322863048,7/14/2014 13:59:00,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM] [SIDE_EFFECT],"[SYMPTOM]
[SIDE_EFFECT]",patients with diabetes in the,n/a,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 14:00:23,,1322863529,7/14/2014 13:59:40,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[TREATS],[TREATS],reduction,na,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 14:18:43,,1322875892,7/14/2014 14:18:34,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Cardiovascular,N/A,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 14:19:07,,1322876210,7/14/2014 14:18:48,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],reduction in,N/A,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912772,7/14/2014 14:23:32,,1322879257,7/14/2014 14:22:57,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[SYMPTOM],[SYMPTOM],reduction in,N/A,199,151,210,185,1,RO-may_treat,907486-FS1,"1]  Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the LOSARTAN INTERVENTION FOR ENDPOINT reduction in HYPERTENSION study (LIFE): a randomised trial against atenolol.",HYPERTENSION,LOSARTAN INTERVENTION FOR ENDPOINT
502912773,7/14/2014 13:01:24,,1322822407,7/14/2014 13:00:44,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],therapy with,n/a,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 13:05:13,,1322824750,7/14/2014 13:04:43,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],and received salvage chemotherapy with,N/A,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 13:18:44,,1322834090,7/14/2014 13:17:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],failed to respond,N/A,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 13:24:36,,1322838198,7/14/2014 13:24:12,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],therapy,N/A,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 13:27:32,,1322840152,7/14/2014 13:26:01,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],failed to respond to induction therapy,did not,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 13:47:12,,1322854481,7/14/2014 13:46:35,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"ACUTE MYELOCYTIC LEUKEMIA CYTOSINE ARABINOSIDE,",n/a,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 14:00:12,,1322863453,7/14/2014 13:59:55,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],received salvage chemotherapy,Na,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 14:07:08,,1322868256,7/14/2014 14:06:46,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],"ACUTE MYELOCYTIC LEUKEMIA CYTOSINE ARABINOSIDE,",N/A,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 14:17:30,,1322875070,7/14/2014 14:17:21,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],CYTOSINE,N/A,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 14:17:33,,1322875129,7/14/2014 14:16:03,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,na,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 14:32:25,,1322885916,7/14/2014 14:32:16,instagc,1.0,27753923,GBR,"","",188.30.192.65,[LOCATION],[LOCATION],chemotherapy with,n/a,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 14:43:49,,1322893651,7/14/2014 14:42:27,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],failed to respond to induction therapy,N/A,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 14:45:55,,1322894955,7/14/2014 14:45:27,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"ACUTE MYELOCYTIC LEUKEMIA CYTOSINE ARABINOSIDE,",n/a,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 14:48:26,,1322896463,7/14/2014 14:47:57,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to respond to,[DIAGNOSE_BY_TEST_OR_DRUG],38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912773,7/14/2014 14:54:08,,1322899787,7/14/2014 14:53:34,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],received salvage chemotherapy with,N/A,38,196,62,216,1,RO-may_treat,907921-FS1,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
502912774,7/14/2014 12:46:43,,1322812471,7/14/2014 12:46:37,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[LOCATION],[LOCATION],BALSALAZIDE,da,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 13:06:32,,1322825710,7/14/2014 13:05:55,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],"patient's use of mesalamine and BALSALAZIDE for are deemed potential triggers,",n/a,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 13:08:54,,1322827367,7/14/2014 13:08:16,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],use of for,N/A,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 13:14:58,,1322831509,7/14/2014 13:14:28,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 13:17:18,,1322833173,7/14/2014 13:16:40,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],use of,na,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 13:32:13,,1322843193,7/14/2014 13:31:30,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.99,[OTHER],[OTHER],for,N/A,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 13:35:45,,1322845915,7/14/2014 13:32:57,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[NONE],[NONE],N/A,BALSALAZIDE IS TAKEN FOR ULCERATIVE COLITIS AS TREATMENT.,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 13:36:54,,1322846778,7/14/2014 13:36:38,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],for,N/A,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 13:56:20,,1322860876,7/14/2014 13:55:56,superrewards,1.0,22551185,GBR,"","",87.113.87.199,[TREATS],[TREATS],use of BALSALAZIDE for ULCERATIVE COLITIS,N/A,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 14:03:12,,1322865645,7/14/2014 14:02:36,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],mesalamine BALSALAZIDE ULCERATIVE COLITIS,N/A,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 14:04:47,,1322866672,7/14/2014 14:04:31,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],Medications,Na,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 14:17:23,,1322875001,7/14/2014 14:17:02,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],use of for,N/A,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 14:18:00,,1322875460,7/14/2014 14:16:40,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],for,N/A,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 14:18:13,,1322875555,7/14/2014 14:18:00,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],known,N/A,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912774,7/14/2014 14:26:51,,1322881730,7/14/2014 14:25:53,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",patient's use of for,N/A,101,85,118,96,1,RO-may_treat,908219-FS1,"Medications associated with PPD are reviewed and the patient's use of mesalamine and BALSALAZIDE for ULCERATIVE COLITIS are deemed potential triggers, given their relative similarity to aspirin, a known trigger of PPD.",ULCERATIVE COLITIS,BALSALAZIDE
502912775,7/14/2014 12:46:28,,1322812348,7/14/2014 12:46:21,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],maintenance,da,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 12:53:24,,1322817112,7/14/2014 12:52:55,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],findings associated with these,n/a,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 12:57:53,,1322820029,7/14/2014 12:57:28,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[IS_A],[IS_A],with these,N/A,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 13:21:02,,1322835581,7/14/2014 13:19:43,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,na,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 13:21:25,,1322835900,7/14/2014 13:20:52,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 13:38:40,,1322848094,7/14/2014 13:37:42,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[IS_A],[IS_A],with these,N/A,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 13:39:20,,1322848551,7/14/2014 13:37:44,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],paper reviews substrates responsible for the induction maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses ECG findings associated with TACHYCARDIAS,N/A,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 13:59:38,,1322863113,7/14/2014 13:58:28,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,na,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 14:06:45,,1322867981,7/14/2014 14:06:24,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SUPRAVENTRICULAR TACHYCARDIA discusses the ECG findings associated with these TACHYCARDIAS,N/A,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 14:14:43,,1322873239,7/14/2014 14:14:34,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],substrates,N/A,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 14:19:54,,1322876723,7/14/2014 14:19:20,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with these,N/A,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 14:34:24,,1322887142,7/14/2014 14:34:18,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",TACHYCARDIAS,n/a,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 14:38:23,,1322889888,7/14/2014 14:37:55,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SUPRAVENTRICULAR TACHYCARDIA TACHYCARDIAS,n/a,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 14:47:55,,1322896176,7/14/2014 14:47:37,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,[ASSOCIATED_WITH],176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912775,7/14/2014 14:52:26,,1322898817,7/14/2014 14:51:52,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],TACHYCARDIA these TACHYCARDIAS,N/A,176,94,187,122,-1,RO-has_definitional_manifestation,904614-FS1,This paper reviews the anatomical substrates responsible for the induction and maintenance of SUPRAVENTRICULAR TACHYCARDIA and discusses the ECG findings associated with these TACHYCARDIAS,TACHYCARDIAS,SUPRAVENTRICULAR TACHYCARDIA
502912776,7/14/2014 12:59:38,,1322821249,7/14/2014 12:59:23,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[IS_A],[IS_A],rare clinical variant,N/A,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 13:10:40,,1322828618,7/14/2014 13:09:51,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],clinical variant,N/A,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 13:26:07,,1322839211,7/14/2014 13:25:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],clinical variant of,N/A,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 13:29:29,,1322841417,7/14/2014 13:28:22,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],is a rare clinical variant of,na,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 13:46:29,,1322853801,7/14/2014 13:45:56,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LUPUS ERYTHEMATOSUS PROFUNDUS LUPUS ERYTHEMATOSUS,n/a,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 13:55:49,,1322860537,7/14/2014 13:55:14,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],clinical variant,na,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 13:58:26,,1322862242,7/14/2014 13:57:47,superrewards,1.0,22551185,GBR,"","",87.113.87.199,[IS_A],[IS_A],is a rare clinical variant,N/A,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 14:02:34,,1322865188,7/14/2014 14:02:19,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],rare clinical variant,Na,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 14:06:00,,1322867446,7/14/2014 14:05:30,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],LUPUS ERYTHEMATOSUS PROFUNDUS is a rare clinical LUPUS ERYTHEMATOSUS,N/A,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 14:32:55,,1322886295,7/14/2014 14:30:59,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],is a rare clinical variant of,N/A,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 14:35:13,,1322887745,7/14/2014 14:35:04,instagc,1.0,27753923,GBR,"","",188.30.192.65,[SIDE_EFFECT],[SIDE_EFFECT],LUPUS ERYTHEMATOSUS PROFUNDUS,n/a,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 14:37:25,,1322889192,7/14/2014 14:37:04,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LUPUS ERYTHEMATOSUS PROFUNDUS LUPUS ERYTHEMATOSUS,n/a,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 14:43:23,,1322893271,7/14/2014 14:43:00,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is a clinical variant,[DIAGNOSE_BY_TEST_OR_DRUG],0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 14:48:56,,1322896728,7/14/2014 14:48:36,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],variant of,N/A,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912776,7/14/2014 14:58:44,,1322902723,7/14/2014 14:58:30,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],is a rare clinical variant,N/a,0,0,28,19,-1,RO-cause_of,900458-FS1,LUPUS ERYTHEMATOSUS PROFUNDUS (panniculitis) is a rare clinical variant of LUPUS ERYTHEMATOSUS,LUPUS ERYTHEMATOSUS PROFUNDUS,LUPUS ERYTHEMATOSUS
502912777,7/14/2014 12:41:35,,1322809166,7/14/2014 12:40:47,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],most prevalent in the form of,n/a,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 12:49:05,,1322814062,7/14/2014 12:48:58,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],INVOLVEMENT,da,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 12:49:32,,1322814352,7/14/2014 12:49:06,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION] [SYMPTOM] [SIDE_EFFECT],"[SYMPTOM]
[MANIFESTATION]
[SIDE_EFFECT]",is most prevalent in the form of,n/a,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 13:07:33,,1322826404,7/14/2014 13:07:04,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],most prevalent in the form of,n/a,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 13:23:37,,1322837590,7/14/2014 13:21:05,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[IS_A],[IS_A],in the form of,na,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 13:28:25,,1322840725,7/14/2014 13:25:44,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[MANIFESTATION],[MANIFESTATION],prevalent in the form of,N/A,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 13:31:26,,1322842729,7/14/2014 13:30:46,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],is most prevalent in the form of,N/A,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 13:33:24,,1322844200,7/14/2014 13:32:58,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],in the form of,N/A,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 13:41:14,,1322849902,7/14/2014 13:40:39,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prevalent in the form,N/A,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 13:47:50,,1322854912,7/14/2014 13:47:18,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CUTANEOUS INVOLVEMENT URTICARIA PIGMENTOSA,n/a,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 13:55:06,,1322859999,7/14/2014 13:54:49,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SIDE_EFFECT],[SIDE_EFFECT],most prevalent,Na,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 13:58:27,,1322862254,7/14/2014 13:57:50,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",prevalent,na,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 14:16:21,,1322874347,7/14/2014 14:16:08,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,N/A,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 14:22:28,,1322878541,7/14/2014 14:21:35,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],is most prevalent in the form of,N/A,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912777,7/14/2014 14:24:25,,1322879856,7/14/2014 14:23:47,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],the form of,N/A,23,78,43,98,1,RO-disease_has_finding,901944-FS1,"In pediatric patients, CUTANEOUS INVOLVEMENT is most prevalent in the form of URTICARIA PIGMENTOSA which is typically asymptomatic or minimally so with resolution by adolescence.",CUTANEOUS INVOLVEMENT,URTICARIA PIGMENTOSA
502912778,7/14/2014 12:48:26,,1322813578,7/14/2014 12:48:18,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],DISEASE,da,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 12:48:28,,1322813645,7/14/2014 12:48:02,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],such classic features,n/a,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 12:52:48,,1322816700,7/14/2014 12:51:34,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",features of as,n/a,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 12:55:57,,1322818782,7/14/2014 12:55:18,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[SYMPTOM],[SYMPTOM],absence of features,N/A,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 12:56:03,,1322818864,7/14/2014 12:55:32,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[IS_A],[IS_A],features of,n/a,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 13:14:55,,1322831461,7/14/2014 13:14:16,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],classic features,na,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 13:20:32,,1322835217,7/14/2014 13:19:06,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],absence of,N/A,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 13:22:26,,1322836687,7/14/2014 13:22:06,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],classic features of,N/A,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 13:23:35,,1322837567,7/14/2014 13:23:21,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],presentation.,N/A,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 13:45:41,,1322853081,7/14/2014 13:44:54,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as,N/A,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 13:48:08,,1322855104,7/14/2014 13:47:18,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",classic features of CELIAC DISEASE as STEATORRHEA,N/A,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 13:52:42,,1322858428,7/14/2014 13:51:21,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",as,n/a,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 13:58:08,,1322861966,7/14/2014 13:57:23,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],features of as and diarrhea,N/A,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 14:03:54,,1322866061,7/14/2014 14:02:52,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[PART_OF],[PART_OF],features of CELIAC DISEASE as STEATORRHEA,N/A,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912778,7/14/2014 14:18:47,,1322875916,7/14/2014 14:17:49,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],classic features of,N/A,58,40,68,54,1,RO-has_manifestation,906282-FS1,The absence of such classic features of CELIAC DISEASE as STEATORRHEA and diarrhea is not an uncommon presentation.,STEATORRHEA,CELIAC DISEASE
502912779,7/14/2014 12:45:19,,1322811620,7/14/2014 12:45:13,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],long,da,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 12:50:36,,1322815089,7/14/2014 12:50:10,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[CONTRAINDICATES],[CONTRAINDICATES],should be discontinued before conception,n/a,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 12:50:47,,1322815237,7/14/2014 12:49:34,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[OTHER],[OTHER],should be discontinued before PREGNANCY is confirmed,WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 13:03:22,,1322823708,7/14/2014 13:02:27,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[CONTRAINDICATES],[CONTRAINDICATES],discontinued,N/A,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 13:10:43,,1322828668,7/14/2014 13:10:14,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CONTRAINDICATES],[CONTRAINDICATES],should be discontinued,na,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 13:15:46,,1322832092,7/14/2014 13:14:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],should be avoided,N/A,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 13:36:37,,1322846616,7/14/2014 13:36:02,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CONTRAINDICATES],[CONTRAINDICATES],should be discontinued,N/A,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 13:54:57,,1322859947,7/14/2014 13:53:57,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],should be discontinued before conception,N/A,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 13:55:27,,1322860284,7/14/2014 13:54:58,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],WARFARIN PREGNANCY,n/a,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 14:18:24,,1322875635,7/14/2014 14:18:14,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],pregnancy,N/A,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 14:18:43,,1322875882,7/14/2014 14:18:12,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CONTRAINDICATES],[CONTRAINDICATES],should be discontinued,N/A,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 14:19:38,,1322876592,7/14/2014 14:18:29,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],soon as,na,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 14:25:25,,1322880708,7/14/2014 14:24:27,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[NONE],[NONE],N/A,Warfarin is something you should not do if you're pregnant. But there is no direct link between the two words.,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 14:35:57,,1322888188,7/14/2014 14:35:50,instagc,1.0,27753923,GBR,"","",188.30.192.65,[SYMPTOM],[SYMPTOM],receive PREGNANCY,n/a,165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912779,7/14/2014 14:44:35,,1322894158,7/14/2014 14:44:09,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]",should be discontinued,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES],165,101,173,109,1,RO-contraindicated_drug,901070-FS1,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
502912780,7/14/2014 12:48:12,,1322813435,7/14/2014 12:47:36,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[SYMPTOM],[SYMPTOM],EPILEPSY SEIZURE,N/A,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 12:51:47,,1322815997,7/14/2014 12:50:58,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and those requiring two medications for SEIZURE,n/a,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 13:03:40,,1322823917,7/14/2014 13:02:55,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],those requiring two medications for,N/A,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 13:07:07,,1322826097,7/14/2014 13:06:19,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 13:19:41,,1322834694,7/14/2014 13:18:24,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],those in whom,na,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 13:35:13,,1322845498,7/14/2014 13:34:28,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],two groups of,N/A,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 13:57:46,,1322861819,7/14/2014 13:56:56,superrewards,1.0,22551185,GBR,"","",87.113.87.199,[MANIFESTATION],[MANIFESTATION],BENIGN EPILEPSY with SEIZURE,N/A,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 14:08:41,,1322869174,7/14/2014 14:08:21,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],BENIGN EPILEPSY SEIZURE,N/A,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 14:25:51,,1322881026,7/14/2014 14:24:26,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM],[SYMPTOM],those in whom seizure control,N/A,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 14:33:50,,1322886794,7/14/2014 14:33:42,instagc,1.0,27753923,GBR,"","",188.30.192.65,[PREVENTS],[PREVENTS],study was,n/a,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 14:35:27,,1322887916,7/14/2014 14:34:20,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],those in whom seizure control,N/A,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 14:43:48,,1322893650,7/14/2014 14:43:19,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[TREATS],[TREATS],BENIGN EPILEPSY SEIZURE,n/a,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 14:45:59,,1322895009,7/14/2014 14:45:34,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]",use of medication,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES],333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 14:48:06,,1322896245,7/14/2014 14:47:12,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],those in whom,N/A,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912780,7/14/2014 14:56:32,,1322901318,7/14/2014 14:56:11,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],medications for control,N/a,333,124,339,139,-1,RO-has_definitional_manifestation,904580-FS1,The objective of this study was to compare the clinical and electroencephalographic features of two groups of children with BENIGN EPILEPSY of childhood with rolandic spikes: those in whom seizure control was attained either without the use of medication or with a single medication (group 1) and those requiring two medications for SEIZURE control (group 2.,SEIZURE,BENIGN EPILEPSY
502912781,7/14/2014 12:54:46,,1322818080,7/14/2014 12:54:10,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[PART_OF],[PART_OF],relation of measures,N/A,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 12:57:55,,1322820071,7/14/2014 12:57:27,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relation,N/A,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 12:59:34,,1322821189,7/14/2014 12:58:56,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",relation of measures of,n/a,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 12:59:49,,1322821359,7/14/2014 12:59:29,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[IS_A],[IS_A],relation of measures,n/a,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 13:04:29,,1322824384,7/14/2014 13:03:23,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and relation,N/A,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 13:18:13,,1322833702,7/14/2014 13:17:54,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relation,N/A,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 13:25:59,,1322839079,7/14/2014 13:23:56,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,I did not select none,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 13:26:39,,1322839517,7/14/2014 13:25:18,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BRAIN LESION and relation of measures of BRAIN CHAMBERS are indices of cognitive dysfunction in multiple sclerosis.,N/A,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 13:43:55,,1322851917,7/14/2014 13:43:21,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[NONE],[NONE],N/A,Both parts of a list,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 13:58:12,,1322862040,7/14/2014 13:57:32,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BRAIN LESION BRAIN CHAMBERS,n/a,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 14:14:10,,1322872858,7/14/2014 14:14:02,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],relation,N/A,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 14:15:59,,1322874139,7/14/2014 14:14:53,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],best indices of,N/A,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 14:24:53,,1322880300,7/14/2014 14:24:22,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],relation of measures of,N/A,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 14:33:32,,1322886613,7/14/2014 14:33:21,instagc,1.0,27753923,GBR,"","",188.30.192.65,[MANIFESTATION],[MANIFESTATION],BRAIN LESION,n/a,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912781,7/14/2014 14:40:43,,1322891524,7/14/2014 14:39:31,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,83,16,96,28,1,RO-has_finding_site,905397-FS1,"Total volume of BRAIN LESION corpus callosum diameter, and relation of measures of BRAIN CHAMBERS and the rest of the brain, are best indices of cognitive dysfunction in multiple sclerosis.",BRAIN CHAMBERS,BRAIN LESION
502912782,7/14/2014 12:45:22,,1322811643,7/14/2014 12:44:33,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],a gene coding for the,n/a,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 12:46:36,,1322812401,7/14/2014 12:46:30,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[LOCATION],[LOCATION],DeltaE1/DeltaE2,da,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 12:55:17,,1322818402,7/14/2014 12:54:48,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[PART_OF],[PART_OF],a gene coding for,N/A,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 12:56:33,,1322819245,7/14/2014 12:56:05,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],protein derived from the Coronavirus causing,n/a,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 13:09:29,,1322827793,7/14/2014 13:08:52,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],gene coding for,na,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 13:19:02,,1322834253,7/14/2014 13:18:36,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],coding,N/A,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 13:25:48,,1322838964,7/14/2014 13:24:53,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[PART_OF],[PART_OF],(SARS COV a gene coding for the,N/A,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 13:39:41,,1322848830,7/14/2014 13:38:58,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[OTHER],[OTHER],for an antibody,N/A,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 13:53:48,,1322859128,7/14/2014 13:51:46,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[PART_OF],[PART_OF],SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for SARS COV RECEPTOR,N/A,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 13:54:18,,1322859525,7/14/2014 13:53:45,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],causing,n/a,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 13:56:09,,1322860787,7/14/2014 13:55:32,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE ACUTE RESPIRATORY SYNDROME SARS COV RECEPTOR,n/a,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 13:57:35,,1322861672,7/14/2014 13:57:13,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],causing,n/a,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 14:01:38,,1322864534,7/14/2014 14:01:04,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM] [LOCATION],"[LOCATION]
[SYMPTOM]",gene coding,na,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 14:03:59,,1322866123,7/14/2014 14:03:42,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[OTHER],[OTHER],gene coding,Na,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912782,7/14/2014 14:09:09,,1322869434,7/14/2014 14:08:42,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[SYMPTOM],[SYMPTOM],SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR,N/A,262,196,278,239,-1,RO-has_causative_agent,903575-FS1,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
502912783,7/14/2014 12:49:14,,1322814164,7/14/2014 12:49:06,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],MINERAL,da,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 12:56:52,,1322819435,7/14/2014 12:56:02,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,[OTHER],[OTHER],can predict risk of,n/a,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 12:59:22,,1322821076,7/14/2014 12:58:34,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],can predict risk of OSTEOPOROSIS,N/A,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 13:02:43,,1322823258,7/14/2014 13:02:24,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],can predict risk,n/a,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 13:21:34,,1322835971,7/14/2014 13:20:31,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[SIDE_EFFECT],[SIDE_EFFECT],may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS,N/A,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 13:24:54,,1322838340,7/14/2014 13:24:37,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],complication,N/A,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 13:30:54,,1322842427,7/14/2014 13:30:07,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],risk of,N/A,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 13:47:17,,1322854553,7/14/2014 13:46:44,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and predict risk,n/a,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 13:52:48,,1322858472,7/14/2014 13:52:13,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],BONE MINERAL METABOLISM OSTEOPOROSIS,n/a,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 14:10:48,,1322870495,7/14/2014 14:10:21,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[TREATS],[TREATS],BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS,N/A,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 14:15:36,,1322873885,7/14/2014 14:15:28,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],MINERAL,N/A,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 14:30:50,,1322884688,7/14/2014 14:30:02,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],can predict risk,N/A,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 14:35:02,,1322887647,7/14/2014 14:34:56,instagc,1.0,27753923,GBR,"","",188.30.192.65,[IS_A],[IS_A],BONE MINERAL METABOLISM,n/a,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 14:46:16,,1322895164,7/14/2014 14:45:58,rewardsspot,1,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BONE MINERAL METABOLISM OSTEOPOROSIS,n/a,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912783,7/14/2014 14:46:33,,1322895336,7/14/2014 14:45:37,vivatic,1,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],can predict risk of,N/A,172,220,194,232,1,RO-disease_has_primary_anatomic_site,902487-FS1,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
502912784,7/14/2014 12:45:12,,1322811521,7/14/2014 12:45:04,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],"pain,",da,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 12:54:09,,1322817652,7/14/2014 12:53:33,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[SYMPTOM],[SYMPTOM],near zero correlations,N/A,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 12:55:54,,1322818745,7/14/2014 12:55:25,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],the latency ANGINA in the patients.,n/a,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 13:09:24,,1322827742,7/14/2014 13:07:46,bitcoinget,1,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],"an idiopathic pain,",N/A,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 13:09:29,,1322827792,7/14/2014 13:08:54,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],the latency to,n/a,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 13:20:47,,1322835375,7/14/2014 13:19:42,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 13:22:59,,1322837110,7/14/2014 13:22:40,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],latency,N/A,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 13:44:53,,1322852525,7/14/2014 13:43:58,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],"and an idiopathic pain, the latency to",N/A,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 13:47:16,,1322854555,7/14/2014 13:44:24,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[NONE],[NONE],N/A,PAINS SHOWED NO CORRELATION,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 13:49:45,,1322856219,7/14/2014 13:48:14,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"near zero correlations between heat, cold, ischemic, and electrical PAINS and idiopathic pain, the latency to EXERCISE INDUCED ANGINA",N/A,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 13:57:12,,1322861431,7/14/2014 13:56:37,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",correlations between,n/a,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 13:58:58,,1322862621,7/14/2014 13:58:13,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],"PAINS idiopathic pain, latency to EXERCISE INDUCED ANGINA",N/A,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 14:05:02,,1322866816,7/14/2014 14:04:48,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],correlations,Na,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 14:17:20,,1322874985,7/14/2014 14:17:12,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],electrical,N/A,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912784,7/14/2014 14:20:52,,1322877476,7/14/2014 14:20:17,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",latency,na,149,194,153,217,-1,RO-has_definitional_manifestation,904623-FS1,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
502912785,7/14/2014 12:54:47,,1322818098,7/14/2014 12:54:24,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",develops features,n/a,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 13:00:06,,1322821521,7/14/2014 12:59:40,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[IS_A],[IS_A],features of,N/A,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 13:06:00,,1322825353,7/14/2014 13:05:35,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[MANIFESTATION],[MANIFESTATION],usually develops,na,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 13:14:27,,1322831222,7/14/2014 13:13:32,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],develops,N/A,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 13:40:38,,1322849516,7/14/2014 13:40:11,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[CAUSES],[CAUSES],develops and has features,N/A,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 13:50:50,,1322856939,7/14/2014 13:50:05,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and chronic,n/a,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 13:57:33,,1322861657,7/14/2014 13:57:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],develops insidiously,Na,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 14:02:51,,1322865402,7/14/2014 14:01:36,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[CAUSES],[CAUSES],MEDICATION OVERUSE HEADACHE develops insidiously and has features of TENSION TYPE HEADACHE.,N/A,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 14:21:58,,1322878277,7/14/2014 14:21:28,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],develops insidiously,na,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 14:23:45,,1322879439,7/14/2014 14:21:31,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER],[OTHER],often has the features of,They display similar symptoms but are not specifically related in a way described by any of the other words,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 14:29:01,,1322883306,7/14/2014 14:28:01,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],usually develops insidiously and often has the features of tension type headache,N/A,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 14:35:49,,1322888086,7/14/2014 14:35:42,instagc,1.0,27753923,GBR,"","",188.30.192.65,[MANIFESTATION] [CAUSES],"[CAUSES]
[MANIFESTATION]",OVERUSE HEADACHE,n/a,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 14:44:40,,1322894136,7/14/2014 14:44:20,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MEDICATION OVERUSE HEADACHE TENSION TYPE HEADACHE.,n/a,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 14:45:32,,1322894774,7/14/2014 14:45:06,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[MANIFESTATION]",usually develops,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [MANIFESTATION],0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912785,7/14/2014 14:48:35,,1322896583,7/14/2014 14:48:07,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],has the features of,N/A,0,122,28,143,-1,RO-has_definitional_manifestation,904986-FS1,? MEDICATION OVERUSE HEADACHE usually develops insidiously and often has the features of tension type headache or chronic TENSION TYPE HEADACHE.,? MEDICATION OVERUSE HEADACHE,TENSION TYPE HEADACHE
502912786,7/14/2014 12:42:32,,1322809823,7/14/2014 12:42:12,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],suggestive of,n/a,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 12:58:18,,1322820351,7/14/2014 12:57:54,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[SYMPTOM],[SYMPTOM],suggestive of PHEOCHROMOCYTOMA,N/A,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 13:06:52,,1322825910,7/14/2014 13:06:05,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggestive of,na,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 13:06:54,,1322825934,7/14/2014 13:06:09,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],suggestive of,N/A,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 13:24:12,,1322837952,7/14/2014 13:23:56,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],suggestive,N/A,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 14:26:32,,1322881478,7/14/2014 14:26:03,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],suggestive of,N/A,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 14:32:47,,1322886124,7/14/2014 14:32:34,instagc,1.0,27753923,GBR,"","",188.30.192.65,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],had episodic,n/a,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 14:43:16,,1322893204,7/14/2014 14:42:41,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[TREATS],[TREATS],HYPERTENSION PHEOCHROMOCYTOMA,n/a,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 14:47:35,,1322895951,7/14/2014 14:47:13,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],had episodic,[DIAGNOSE_BY_TEST_OR_DRUG],63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 14:49:21,,1322896934,7/14/2014 14:48:57,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],suggestive of,N/A,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 14:57:12,,1322901832,7/14/2014 14:57:01,instagc,1,18960682,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],suggestive of,N/a,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 15:00:28,,1322903763,7/14/2014 14:59:59,clixsense,1,19294877,USA,MA,Boston,140.241.0.20,[SYMPTOM],[SYMPTOM],suggestive of,N/A,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 15:02:12,,1322904760,7/14/2014 15:01:43,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],suggestive of,n/a,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 15:02:48,,1322905133,7/14/2014 15:02:19,instagc,1,28519532,USA,IA,Honey Creek,12.73.110.26,[SYMPTOM],[SYMPTOM],suggestive of,N/A,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912786,7/14/2014 15:03:22,,1322905442,7/14/2014 15:02:39,prodege,1,27934334,GBR,Q2,Wokingham,86.166.73.21,[SYMPTOM],[SYMPTOM],suggestive of,N/A,63,90,74,106,1,RO-disease_may_have_finding,902644-FS1,"On questioning patient had episodic palpitations, flushing and HYPERTENSION suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
502912787,7/14/2014 12:56:31,,1322819239,7/14/2014 12:55:55,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SIDE_EFFECT],[SIDE_EFFECT],improved outcome has not been demonstrated conclusively,n/a,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 12:58:55,,1322820814,7/14/2014 12:56:53,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",increased drug clearance,n/a,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 12:59:16,,1322821031,7/14/2014 12:58:33,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],increased,N/A,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 13:04:16,,1322824232,7/14/2014 13:03:29,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],been demonstrated conclusively,n/a,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 13:18:40,,1322834073,7/14/2014 13:18:02,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],and improved outcome has not been demonstrated conclusively for any,N/A,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 13:28:49,,1322840964,7/14/2014 13:28:16,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DRUGS,N/A,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 13:29:30,,1322841440,7/14/2014 13:28:16,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[CAUSES],[CAUSES],shown definitively,na,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 13:39:57,,1322849030,7/14/2014 13:39:14,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CONTRAINDICATES],[CONTRAINDICATES],DRUGS OVERDOSE,n/a,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 13:43:20,,1322851475,7/14/2014 13:42:50,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[NONE],[NONE],N/A,No relation implied by the sentence,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 13:54:35,,1322859737,7/14/2014 13:54:14,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],any,Na,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 14:04:34,,1322866485,7/14/2014 14:04:04,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],conclusively,na,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 14:10:02,,1322869925,7/14/2014 14:09:39,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],DRUGS OVERDOSE,N/A,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 14:14:33,,1322873115,7/14/2014 14:14:20,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],only,N/A,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 14:21:23,,1322877789,7/14/2014 14:20:34,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DRUGS OVERDOSE,N/A,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912787,7/14/2014 14:41:44,,1322892036,7/14/2014 14:40:55,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DRUGS OVERDOSE,n/a,77,151,81,159,-1,RO-has_causative_agent,903898-FS1,"However, increased drug clearance has been shown definitively for only a few DRUGS and improved outcome has not been demonstrated conclusively for any OVERDOSE",DRUGS,OVERDOSE
502912788,7/14/2014 12:48:16,,1322813484,7/14/2014 12:48:10,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CONTRAINDICATES],[CONTRAINDICATES],phenomenon,da,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 13:01:38,,1322822559,7/14/2014 13:01:08,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],systemic conditions or primary disorder,N/A,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 13:07:36,,1322826440,7/14/2014 13:06:55,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or may represent,na,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 13:17:01,,1322833004,7/14/2014 13:16:19,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],may be encountered,N/A,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 13:32:09,,1322843179,7/14/2014 13:30:37,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Elevated platelet systemic conditions (THROMBOCYTOSIS) or represent primary disorder (THROMBOCYTHEMIA,N/A,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 13:34:01,,1322844613,7/14/2014 13:33:25,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Elevated platelet counts,N/A,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 13:38:33,,1322847959,7/14/2014 13:37:58,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(THROMBOCYTOSIS) (THROMBOCYTHEMIA,n/a,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 13:43:57,,1322851924,7/14/2014 13:42:47,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],may represent of,N/A,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 13:59:14,,1322862836,7/14/2014 13:58:55,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or may,Na,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 14:14:46,,1322873318,7/14/2014 14:14:05,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],represent,na,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 14:15:45,,1322873982,7/14/2014 14:14:58,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or may represent a primary disorder of the bone marrow,N/A,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 14:17:00,,1322874773,7/14/2014 14:16:51,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],secondary,N/A,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 14:20:33,,1322877199,7/14/2014 14:19:37,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],systemic conditions or disorder of bone marrow,N/A,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 14:29:26,,1322883654,7/14/2014 14:26:53,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER],[OTHER],or may represent,The two conditions share symptoms but are not otherwise related in the ways described by any of the other words,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912788,7/14/2014 14:34:16,,1322887069,7/14/2014 14:34:07,instagc,1.0,27753923,GBR,"","",188.30.192.65,[PREVENTS],[PREVENTS],encountered reactive,n/a,188,116,202,130,-1,RO-has_definitional_manifestation,904548-FS1,Elevated platelet counts may be encountered as a reactive phenomenon secondary to a variety of systemic conditions (THROMBOCYTOSIS) or may represent a primary disorder of the bone marrow (THROMBOCYTHEMIA,THROMBOCYTHEMIA,THROMBOCYTOSIS
502912789,7/14/2014 12:45:47,,1322811870,7/14/2014 12:45:39,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],nuclear,da,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 12:56:19,,1322819080,7/14/2014 12:55:57,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[PART_OF],[PART_OF],in,n/a,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 13:12:49,,1322830022,7/14/2014 13:10:51,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS,N/A,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 13:18:01,,1322833577,7/14/2014 13:17:30,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],of in 32,N/A,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 13:18:35,,1322834009,7/14/2014 13:18:14,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],in,N/A,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 14:04:13,,1322866280,7/14/2014 14:04:00,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],assessed grades,Na,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 14:11:06,,1322870710,7/14/2014 14:10:49,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[PREVENTS],[PREVENTS],DYSPLASIA 32 COLORECTAL ADENOMATOUS POLYPS,N/A,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 14:20:16,,1322876971,7/14/2014 14:19:39,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM] [LOCATION],"[LOCATION]
[SYMPTOM]",in 32,na,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 14:32:54,,1322886256,7/14/2014 14:32:48,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CAUSES],[CAUSES],"degree dysplasia,",n/a,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 14:42:17,,1322892576,7/14/2014 14:41:55,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DYSPLASIA COLORECTAL ADENOMATOUS POLYPS,n/a,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 14:47:12,,1322895739,7/14/2014 14:46:51,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were compared with,[ASSOCIATED_WITH],129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 14:50:12,,1322897474,7/14/2014 14:49:23,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],grades in,N/A,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 14:58:12,,1322902402,7/14/2014 14:58:00,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],in 32,N/a,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 15:01:12,,1322904229,7/14/2014 15:00:29,clixsense,1.0,19294877,USA,MA,Boston,140.241.0.20,[MANIFESTATION],[MANIFESTATION],DYSPLASIA in COLORECTAL POLYPS,N/A,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912789,7/14/2014 15:01:42,,1322904541,7/14/2014 15:01:09,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],in,n/a,129,145,137,174,1,RO-disease_has_finding,901557-FS1,"In order to objectify the degree of dysplasia, results of nuclear and cellular morphometry were compared with assessed grades of DYSPLASIA in 32 COLORECTAL ADENOMATOUS POLYPS",DYSPLASIA,COLORECTAL ADENOMATOUS POLYPS
502912790,7/14/2014 12:49:24,,1322814303,7/14/2014 12:49:16,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[LOCATION],[LOCATION],and,da,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 13:10:11,,1322828321,7/14/2014 13:09:32,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],has a more,na,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 13:16:17,,1322832435,7/14/2014 13:15:47,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],is a,N/A,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 13:28:21,,1322840672,7/14/2014 13:27:33,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],and has a more,this keeps popping up,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 13:34:32,,1322845085,7/14/2014 13:34:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has a more,N/A,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 13:36:54,,1322846765,7/14/2014 13:36:15,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BLASTOID MANTLE CELL LYMPHOMA (BV MCL) AGGRESSIVE CLINICAL COURSE,n/a,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 13:41:58,,1322850394,7/14/2014 13:40:47,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[PART_OF],[PART_OF],BLASTOID MANTLE CELL rare variant has a more AGGRESSIVE CLINICAL COURSE,N/A,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 13:56:00,,1322860680,7/14/2014 13:53:56,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has a more,N/A,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 13:58:10,,1322861997,7/14/2014 13:57:36,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[MANIFESTATION],[MANIFESTATION],variant,n/a,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 14:03:41,,1322865903,7/14/2014 14:03:25,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],rare variant,Na,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 14:09:38,,1322869710,7/14/2014 14:09:11,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],BLASTOID MANTLE CELL LYMPHOMA MCL) AGGRESSIVE CLINICAL COURSE,N/A,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 14:10:11,,1322870041,7/14/2014 14:09:33,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],COURSE,N/A,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 14:28:00,,1322882538,7/14/2014 14:27:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],is a rare variant and has a more,N/A,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 14:32:06,,1322885712,7/14/2014 14:31:55,instagc,1.0,27753923,GBR,"","",188.30.192.65,[LOCATION],[LOCATION],MCL) rare,n/a,72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912790,7/14/2014 14:42:58,,1322893028,7/14/2014 14:42:35,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is variant,[DIAGNOSE_BY_TEST_OR_DRUG],72,0,97,38,1,RO-disease_may_have_finding,902768-FS1,BLASTOID MANTLE CELL LYMPHOMA (BV MCL) is a rare variant and has a more AGGRESSIVE CLINICAL COURSE,AGGRESSIVE CLINICAL COURSE,BLASTOID MANTLE CELL LYMPHOMA (BV MCL)
502912791,7/14/2014 12:45:59,,1322811993,7/14/2014 12:45:23,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in a context of,n/a,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 12:47:35,,1322813060,7/14/2014 12:47:27,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],ASPHYXIATION,da,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 13:02:53,,1322823372,7/14/2014 13:02:24,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SIDE_EFFECT],[SIDE_EFFECT],form of context,n/a,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 13:23:20,,1322837478,7/14/2014 13:23:00,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],form,N/A,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 13:27:46,,1322840276,7/14/2014 13:26:41,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in a context of,N/A,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 13:36:17,,1322846285,7/14/2014 13:35:37,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in context of,na,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 13:51:27,,1322857492,7/14/2014 13:50:46,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[LOCATION],[LOCATION],SEXUAL ASPHYXIATION AUTOEROTIC ASPHYXIA,n/a,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 14:01:03,,1322864150,7/14/2014 14:00:25,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SIDE_EFFECT],[SIDE_EFFECT],involving,na,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 14:03:22,,1322865763,7/14/2014 14:03:06,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],typical form,Na,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 14:07:31,,1322868473,7/14/2014 14:07:09,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],"SEXUAL ASPHYXIATION described, involving young hanging, context of AUTOEROTIC ASPHYXIA",N/A,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 14:09:54,,1322869872,7/14/2014 14:08:29,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[SYMPTOM],[SYMPTOM],"typical form of SEXUAL ASPHYXIATION described, AUTOEROTIC ASPHYXIA",N/A,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 14:12:07,,1322871434,7/14/2014 14:11:47,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],"is described,",N/A,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 14:14:52,,1322873377,7/14/2014 14:14:44,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SIDE_EFFECT],[SIDE_EFFECT],ASPHYXIATION,N/A,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 14:21:33,,1322877920,7/14/2014 14:19:55,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],A case of a typical form of in a context of,N/A,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912791,7/14/2014 14:33:03,,1322886329,7/14/2014 14:32:56,instagc,1.0,27753923,GBR,"","",188.30.192.65,[PREVENTS],[PREVENTS],SEXUAL ASPHYXIATION,n/a,109,28,127,47,-1,RO-cause_of,900348-FS1,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
502912792,7/14/2014 12:47:27,,1322812997,7/14/2014 12:47:02,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],are of similar efficacy in prevention of,n/a,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 12:56:01,,1322818845,7/14/2014 12:55:35,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],efficacy in prevention,n/a,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 13:11:12,,1322828863,7/14/2014 13:10:41,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[PREVENTS],[PREVENTS],efficacy in prevention of,N/A,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 13:31:41,,1322842913,7/14/2014 13:31:18,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[PREVENTS],[PREVENTS],in prevention of,N/A,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 13:32:06,,1322843155,7/14/2014 13:31:26,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PREVENTS],[PREVENTS],in prevention,N/A,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 13:52:23,,1322858207,7/14/2014 13:51:06,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[OTHER],[OTHER],SUCRALFATE are of similar efficacy in prevention of,N/a,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 13:59:51,,1322863238,7/14/2014 13:57:46,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[PREVENTS],[PREVENTS],SUCRALFATE are prevention of NSAID ASSOCIATED DUODENAL ULCERS,N/A,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 14:03:05,,1322865562,7/14/2014 14:02:49,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[PREVENTS],[PREVENTS],similar efficacy prevention,Na,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 14:18:00,,1322875402,7/14/2014 14:17:51,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in prevention,N/A,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 14:23:56,,1322879582,7/14/2014 14:23:32,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PREVENTS],[PREVENTS],in prevention of,N/A,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 14:33:56,,1322886880,7/14/2014 14:33:51,instagc,1.0,27753923,GBR,"","",188.30.192.65,[SYMPTOM],[SYMPTOM],SUCRALFATE similar,v,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 14:45:24,,1322894638,7/14/2014 14:45:07,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[PREVENTS],[PREVENTS],SUCRALFATE NSAID ASSOCIATED DUODENAL ULCERS,n/a,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 14:46:24,,1322895280,7/14/2014 14:46:00,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[PREVENTS],[PREVENTS],efficacy in prevention,[PREVENTS],84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 14:51:51,,1322898380,7/14/2014 14:51:25,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[PREVENTS],[PREVENTS],similar efficacy in prevention,N/A,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912792,7/14/2014 14:56:44,,1322901514,7/14/2014 14:56:33,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PREVENTS],[PREVENTS],in prevention of,N/a,84,32,115,42,1,RO-may_prevent,907062-FS1,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
502912793,7/14/2014 12:57:49,,1322820024,7/14/2014 12:56:34,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[IS_A],[IS_A],has reemerged,n/a,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 12:58:12,,1322820281,7/14/2014 12:57:49,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],institution of childhood vaccination with DIPHTHERIA TOXOID,n/a,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 13:07:35,,1322826400,7/14/2014 13:07:08,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],vaccination with,N/A,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 13:12:15,,1322829608,7/14/2014 13:11:12,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[PREVENTS],[PREVENTS],vaccination with,N/A,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 13:20:12,,1322835005,7/14/2014 13:19:54,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PREVENTS],[PREVENTS],vaccination,N/A,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 13:24:20,,1322838025,7/14/2014 13:23:12,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[PREVENTS],[PREVENTS],was controlled after the institution vaccination with,N/A,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 13:27:51,,1322840317,7/14/2014 13:26:40,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",diphtheria controlled with DIPHTHERIA TOXOID,N/A,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 13:31:17,,1322842605,7/14/2014 13:30:56,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[PREVENTS],[PREVENTS],childhood vaccination with,N/A,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 13:39:09,,1322848418,7/14/2014 13:38:38,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIPHTHERIA TOXOID epidemic DIPHTHERIA,n/a,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 13:40:48,,1322849647,7/14/2014 13:39:28,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[NONE],[NONE],N/A,DIPTHERIA TOXOID PREVENTS/REDUCES DIPTHERIA,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 14:03:17,,1322865728,7/14/2014 14:02:47,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has reemerged,na,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 14:06:53,,1322868077,7/14/2014 14:06:12,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],childhood vaccination with DIPHTHERIA TOXOID,N/A,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 14:13:51,,1322872727,7/14/2014 14:13:43,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],approximately,N/A,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 14:26:03,,1322881133,7/14/2014 14:25:26,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],vaccination,N/A,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912793,7/14/2014 14:34:46,,1322887422,7/14/2014 14:34:41,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CAUSES],[CAUSES],New Independent,n/a,114,114,123,131,1,RO-may_prevent,907064-FS1,"Although diphtheria was controlled for approximately 30 years after the institution of childhood vaccination with DIPHTHERIA TOXOID in the late 1950s, epidemic DIPHTHERIA has reemerged in the New Independent States (NIS) of the former Soviet Union (1,2) (Figures 1 and 2.",DIPHTHERIA,DIPHTHERIA TOXOID
502912794,7/14/2014 12:47:52,,1322813196,7/14/2014 12:47:45,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],autoimmune,da,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 12:52:54,,1322816719,7/14/2014 12:51:57,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the incidence in clustered,n/a,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 12:53:10,,1322816922,7/14/2014 12:52:19,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[MANIFESTATION],[MANIFESTATION],CIRRHOSIS,N/A,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 13:16:55,,1322832889,7/14/2014 13:16:33,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[LOCATION],[LOCATION],In,N/A,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 13:26:48,,1322839650,7/14/2014 13:26:17,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],"livers with or without cirrhosis,",N/A,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 13:53:28,,1322858963,7/14/2014 13:52:52,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LIVERS CIRRHOSIS,n/a,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 13:55:31,,1322860305,7/14/2014 13:55:07,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],autoimmune etiology livers,Na,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 14:08:27,,1322869093,7/14/2014 14:05:14,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[SYMPTOM],[SYMPTOM],In chronic active hepatitis of viral and autoimmune etiology with or without LIVERS CIRRHOSIS,N/A,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 14:13:42,,1322872630,7/14/2014 14:13:16,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],etiology,N/A,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 14:33:19,,1322886493,7/14/2014 14:33:12,instagc,1.0,27753923,GBR,"","",188.30.192.65,[CAUSES],[CAUSES],CIRRHOSIS respectively.,n/a,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 14:39:44,,1322890867,7/14/2014 14:39:21,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LIVERS CIRRHOSIS,n/a,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 14:41:54,,1322892256,7/14/2014 14:40:55,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[CAUSES],[CAUSES],in clustered,[CAUSES],226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 14:53:33,,1322899458,7/14/2014 14:52:28,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],In autoimmune etiology LIVERS,N/A,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 14:57:58,,1322902308,7/14/2014 14:57:35,instagc,1.0,18960682,GBR,"","",86.29.147.112,[LOCATION],[LOCATION],incidence of,N/a,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912794,7/14/2014 15:02:40,,1322905065,7/14/2014 15:01:12,clixsense,1.0,19294877,USA,MA,Boston,140.241.0.20,[OTHER],[OTHER],"with cirrhosis, LIVERS CIRRHOSIS",N/A,226,360,231,369,1,RO-disease_has_primary_anatomic_site,902370-FS1,"In chronic active hepatitis of viral (132 cases) and autoimmune etiology livers (20 cases) with or without cirrhosis, the incidence of membranous expression of Lewis Y in clustered hepatocytes of viral and autoimmune etiology LIVERS was 21 and 0% of mild chronic active hepatitis; 69 and 25% of moderate degree; 85 and 50% of severe degree; and 87 and 100% of CIRRHOSIS respectively.",LIVERS,CIRRHOSIS
502912795,7/14/2014 12:43:02,,1322810121,7/14/2014 12:42:33,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],two positive responses were demonstrated,n/a,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 12:53:22,,1322817081,7/14/2014 12:52:50,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],two positive responses to,n/a,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 13:00:24,,1322821752,7/14/2014 13:00:07,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],two positive responses,N/A,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 13:06:19,,1322825559,7/14/2014 13:05:29,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],responses to,N/A,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 13:08:24,,1322827099,7/14/2014 13:07:59,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],two positive responses to,n/a,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 13:10:49,,1322828699,7/14/2014 13:08:18,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[IS_A] [SIDE_EFFECT],"[SIDE_EFFECT]
[IS_A]",two positive responses to USDA TUBERCULIN were demonstrated,N/A,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 13:15:27,,1322831834,7/14/2014 13:14:59,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],two positive responses,na,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 13:17:34,,1322833299,7/14/2014 13:17:13,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],responses,N/A,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 13:18:59,,1322834216,7/14/2014 13:18:41,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],two positive responses to,N/A,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 13:23:08,,1322837280,7/14/2014 13:22:45,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],positive responses to,N/A,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 13:37:43,,1322847381,7/14/2014 13:35:43,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],In group knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN,N/A,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 13:44:29,,1322852306,7/14/2014 13:43:55,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULOSIS USDA TUBERCULIN,n/a,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 14:11:06,,1322870729,7/14/2014 14:10:52,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],positive responses to,N/A,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 14:14:52,,1322873371,7/14/2014 14:13:50,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],two positive responses,N/A,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912795,7/14/2014 14:16:50,,1322874614,7/14/2014 14:16:38,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],knwon,N/A,59,98,70,113,1,RO-may_diagnose,906772-FS1,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
502912796,7/14/2014 12:47:44,,1322813149,7/14/2014 12:47:36,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ACETAMINOPHEN,da,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 12:49:50,,1322814594,7/14/2014 12:49:25,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],in alleviating,n/a,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 12:58:31,,1322820561,7/14/2014 12:57:56,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],alleviating,N/A,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 13:01:31,,1322822466,7/14/2014 13:01:12,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],alleviating,N/A,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 13:03:28,,1322823761,7/14/2014 13:03:05,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],in alleviating,n/a,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 13:22:43,,1322836923,7/14/2014 13:22:27,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],Efficacy and safety of,N/A,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 13:25:28,,1322838718,7/14/2014 13:25:11,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],alleviating,N/A,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 13:25:42,,1322838887,7/14/2014 13:22:59,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[NONE],[NONE],N/A,"ACETAMINOPHEN ALLEVIATES OR TREATS MIGRAINE NOT THE OTHER WAY AROUND. IF YOU PUT THE WORD MIGRAINE FIRST, THE CHOICES DO NOT PROVIDE A LOGICAL ANSWER.",112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 13:25:47,,1322838962,7/14/2014 13:25:16,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[TREATS],[TREATS],alleviating,na,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 13:37:47,,1322847415,7/14/2014 13:37:09,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[OTHER],[OTHER],in alleviating,N/A,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 13:45:49,,1322853173,7/14/2014 13:45:13,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],ACETAMINOPHEN MIGRAINE HEADACHE PAIN,n/a,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 13:48:13,,1322855147,7/14/2014 13:46:58,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],in alleviating,N/A,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 13:59:53,,1322863267,7/14/2014 13:59:40,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],Efficacy safety alleviating,Na,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 14:16:07,,1322874212,7/14/2014 14:15:54,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Efficacy,N/A,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912796,7/14/2014 14:17:01,,1322874743,7/14/2014 14:16:45,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],in alleviating,N/A,112,61,133,74,1,RO-may_treat,907500-FS1,"Lipton RB, Stewart WF, Ryan RE et al. Efficacy and safety of ACETAMINOPHEN aspirin, and caffeine in alleviating MIGRAINE HEADACHE PAIN",MIGRAINE HEADACHE PAIN,ACETAMINOPHEN
502912797,7/14/2014 12:46:19,,1322812242,7/14/2014 12:46:12,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],in,da,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 13:00:07,,1322821558,7/14/2014 12:59:17,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 13:00:29,,1322821826,7/14/2014 12:59:51,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],a frequent event after,n/a,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 13:19:54,,1322834846,7/14/2014 13:19:01,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,"These are unrelated in the text, I can't see how they are anyway.",363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 13:22:04,,1322836384,7/14/2014 13:20:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],in patients with,N/A,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 13:22:21,,1322836620,7/14/2014 13:21:54,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 13:22:57,,1322837090,7/14/2014 13:19:52,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assessment of severity of tissue hypothyroidism,N/A,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 13:25:18,,1322838665,7/14/2014 13:23:28,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[SYMPTOM] [ASSOCIATED_WITH] [PART_OF],"[SYMPTOM]
[ASSOCIATED_WITH]
[PART_OF]",in assessment of severity of tissue hypothyroidism OVERT PRIMARY THYROID FAILURE:,N/A,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 13:34:42,,1322845180,7/14/2014 13:33:51,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[SYMPTOM],[SYMPTOM],in patients with,na,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 13:41:40,,1322850206,7/14/2014 13:40:47,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],OVERT PRIMARY THYROID FAILURE: HYPOTHYROIDISM:,n/a,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 13:56:36,,1322861054,7/14/2014 13:55:55,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[SYMPTOM],[SYMPTOM],thyroid disease using,n/a,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 14:04:59,,1322866787,7/14/2014 14:04:18,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey Disorders of sodium balance Cancer HYPOTHYROIDISM:,N/A,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 14:15:01,,1322873430,7/14/2014 14:14:53,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],event,N/A,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 14:21:29,,1322877850,7/14/2014 14:18:45,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[NONE],[NONE],N/A,"It seems from the sentence structure that these are two terms within a list, but not directly related to each other. Use of a colon (:) before each term confirms this",363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912797,7/14/2014 14:30:01,,1322884139,7/14/2014 14:28:56,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with,N/A,363,455,391,469,1,RO-disease_has_primary_anatomic_site,902253-FS1,progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score  Subclinical hypothyroidism and functional mobility in older adults  British Medical Journal  Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with OVERT PRIMARY THYROID FAILURE: cross sectional survey  Disorders of sodium balance  Cancer  HYPOTHYROIDISM: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma  Journal of the American Medical Association  Radiation dose response relationships for thyroid nodules and autoimmune thyroid diseases in.,OVERT PRIMARY THYROID FAILURE,HYPOTHYROIDISM
502912798,7/14/2014 12:47:07,,1322812755,7/14/2014 12:46:19,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[OTHER],[OTHER],as well as,N/A,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 12:48:01,,1322813302,7/14/2014 12:47:28,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],treating as well as,n/a,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 12:48:44,,1322813834,7/14/2014 12:48:37,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],sensitivity,da,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 13:03:26,,1322823759,7/14/2014 13:02:54,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],antibiotic of choice for treating,n/a,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 13:08:52,,1322827366,7/14/2014 13:08:25,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,n/a,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 13:16:38,,1322832723,7/14/2014 13:16:08,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,na,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 13:19:40,,1322834690,7/14/2014 13:18:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],"ofloxacin,",N/A,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 13:19:50,,1322834823,7/14/2014 13:17:37,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[NONE],[NONE],N/A,"SPECTINOMYCIN TREATS GONORRHEA, THE CHOICES MAKES IT LOOK LIKE GONORRHEA ""TREATS"" SPECTINOMYCIN. SO ""NONE"" SHOULD BE THE CHOICE AS THERE IS NO WORD TO LINK THE TWO WORDS.",107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 13:24:51,,1322838319,7/14/2014 13:24:21,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],treating,N/A,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 13:56:21,,1322860880,7/14/2014 13:55:42,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],as well as,N/A,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 14:12:23,,1322871643,7/14/2014 14:12:06,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[PREVENTS],[PREVENTS],UNCOMPLICATED GONORRHEA SPECTINOMYCIN,N/A,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 14:27:18,,1322882076,7/14/2014 14:26:33,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,N/A,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 14:32:32,,1322885968,7/14/2014 14:32:26,instagc,1.0,27753923,GBR,"","",188.30.192.65,[SYMPTOM],[SYMPTOM],SPECTINOMYCIN and,n/a,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 14:40:06,,1322891093,7/14/2014 14:39:45,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[TREATS],[TREATS],for treating,[TREATS],107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912798,7/14/2014 14:46:39,,1322895400,7/14/2014 14:46:20,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],UNCOMPLICATED GONORRHEA SPECTINOMYCIN,n/a,107,142,129,155,1,RO-may_treat,908238-FS1,"The control strains exhibited considerable sensitivity to ofloxacin, the antibiotic of choice for treating UNCOMPLICATED GONORRHEA as well as SPECTINOMYCIN and ceftriaxone.",UNCOMPLICATED GONORRHEA,SPECTINOMYCIN
502912799,7/14/2014 12:45:54,,1322811923,7/14/2014 12:45:49,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],food,da,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 13:00:48,,1322821969,7/14/2014 13:00:30,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],which reduces the risk of,n/a,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 13:01:18,,1322822324,7/14/2014 13:00:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],reduces,N/A,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 13:22:01,,1322836333,7/14/2014 13:20:16,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]",(e.gFOLIC ACID reduces NEURAL TUBE DEFECTS,N/A,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 13:25:13,,1322838548,7/14/2014 13:24:29,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[PREVENTS],[PREVENTS],reduces risk,na,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 13:25:43,,1322838909,7/14/2014 13:25:29,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],reduces,N/A,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 13:37:41,,1322847341,7/14/2014 13:35:47,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[NONE],[NONE],N/A,NEURAL TUBE DEFECTS CAN BE REDUCED BY FOLIC ACID. THE CHOICES DO NOT REFLECT ANY RELATION AS THE WORD ORDER IS REVERSE.,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 13:46:42,,1322853972,7/14/2014 13:46:13,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],reduces the risk,n/a,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 13:57:17,,1322861493,7/14/2014 13:56:56,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[PREVENTS],[PREVENTS],reduces,Na,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 13:58:32,,1322862308,7/14/2014 13:58:13,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[TREATS],[TREATS],reduces the risk of,n/a,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 14:18:28,,1322875642,7/14/2014 14:17:33,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[PREVENTS],[PREVENTS],reduces the risk,na,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 14:18:33,,1322875714,7/14/2014 14:18:24,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],food,N/A,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 14:19:36,,1322876569,7/14/2014 14:19:08,instagc,1.0,13763729,USA,"","",75.182.89.225,[PREVENTS],[PREVENTS],reduces the risk,N/A,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 14:34:20,,1322887123,7/14/2014 14:32:57,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PREVENTS],[PREVENTS],which reduces the risk of,N/A,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912799,7/14/2014 14:36:14,,1322888467,7/14/2014 14:36:08,instagc,1.0,27753923,GBR,"","",188.30.192.65,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",food product,n/a,145,108,163,118,1,RO-may_prevent,907227-FS1,"At the same time, regulations may forbid claims that a food product prevents disease, even when it does (e.gFOLIC ACID which reduces the risk of NEURAL TUBE DEFECTS",NEURAL TUBE DEFECTS,FOLIC ACID
502912800,7/14/2014 12:47:26,,1322813003,7/14/2014 12:47:17,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],NNT,da,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 12:48:41,,1322813793,7/14/2014 12:47:00,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[PREVENTS],[PREVENTS],in preventing early vomiting,n/a,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 12:50:09,,1322814801,7/14/2014 12:49:51,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],in preventing early vomiting,n/a,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 12:50:26,,1322814997,7/14/2014 12:50:11,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[TREATS],[TREATS],preventing early vomiting,N/A,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 13:02:25,,1322823034,7/14/2014 12:59:15,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[NONE],[NONE],N/A,The word VOMITING came first and the choices does not provide a relation to ANTIEMETICS. It should be VOMITING is treated or prevented by ANTiEMETCIS,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 13:19:54,,1322834865,7/14/2014 13:19:34,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PREVENTS],[PREVENTS],preventing,N/A,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 13:28:14,,1322840607,7/14/2014 13:27:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[PREVENTS],[PREVENTS],in preventing,N/A,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 13:28:15,,1322840609,7/14/2014 13:26:54,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[PREVENTS],[PREVENTS],in preventing,na,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 13:30:35,,1322842221,7/14/2014 13:29:41,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",techniques were ANTIEMETICS preventing vomiting,N/A,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 13:40:06,,1322849141,7/14/2014 13:38:41,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[NONE],[NONE],n/a,animentics stop vomiting not the other way around,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 13:54:48,,1322859818,7/14/2014 13:54:36,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],Nonpharmacologic techniques,Na,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 13:54:52,,1322859885,7/14/2014 13:54:10,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[PREVENTS],[PREVENTS],ANTIEMETICS VOMITING,n/a,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 13:57:11,,1322861417,7/14/2014 13:56:32,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",preventing,na,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 13:58:53,,1322862547,7/14/2014 13:58:27,superrewards,1.0,22551185,GBR,"","",87.113.87.199,[PREVENTS],[PREVENTS],in preventing early vomiting,N/A,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912800,7/14/2014 14:16:39,,1322874541,7/14/2014 14:15:46,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PREVENTS],[PREVENTS],ANTIEMETICS in preventing early vomiting,N/A,166,44,173,55,1,RO-may_prevent,907029-FS1,Nonpharmacologic techniques were similar to ANTIEMETICS in preventing early vomiting (RR = 0.89 [95% confidence interval 0.47 1.67]; NNT = 63 [10 infinity]) and late VOMITING (RR = 0.80 [0.35 1.81]; NNT = 25 [5 infinity]) in adults.,VOMITING,ANTIEMETICS
502912801,7/14/2014 12:44:32,,1322811045,7/14/2014 12:44:03,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],(atopic dermatitis; bronchial asthma; ALLERGIC RHINITIS,n/a,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 12:46:11,,1322812143,7/14/2014 12:46:04,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],(atopic,da,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 12:59:28,,1322821115,7/14/2014 12:58:52,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[MANIFESTATION],[MANIFESTATION],Incidence and relative risk,n/a,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 13:02:01,,1322822819,7/14/2014 13:01:25,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Incidence and relative risk of,n/a,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 13:08:24,,1322827113,7/14/2014 13:07:36,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],was analyzed,N/A,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 13:16:32,,1322832655,7/14/2014 13:16:07,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PART_OF],[PART_OF],ALLERGIC RHINITIS AR),N/A,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 13:18:22,,1322833806,7/14/2014 13:17:20,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR)",na,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 13:25:01,,1322838404,7/14/2014 13:24:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],ALLERGIC RHINITIS AR),N/A,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 13:41:45,,1322850242,7/14/2014 13:41:16,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[OTHER],[OTHER],of,N/A,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 13:50:33,,1322856760,7/14/2014 13:49:35,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATOPIC DISEASE ALLERGIC RHINITIS AR),n/a,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 13:51:00,,1322857172,7/14/2014 13:49:08,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],Incidence and relative risk of in,N/A,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 13:58:54,,1322862579,7/14/2014 13:58:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],Incidence relative,Na,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 14:15:26,,1322873723,7/14/2014 14:14:47,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SIDE_EFFECT] [MANIFESTATION],"[MANIFESTATION]
[SIDE_EFFECT]",relative risk,na,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 14:17:48,,1322875295,7/14/2014 14:17:24,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],ATOPIC DISEASE ALLERGIC RHINITIS,N/A,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912801,7/14/2014 14:17:49,,1322875326,7/14/2014 14:17:41,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],asthma;,N/A,92,31,111,45,-1,RO-cause_of,900077-FS1,"Incidence and relative risk of ATOPIC DISEASE (atopic dermatitis; AD, bronchial asthma; BA, ALLERGIC RHINITIS AR) in Japanese infants and children in relation to their nutrition in infancy was analyzed from the data of the epidemiological survey which was conducted for 10,000 mothers of infants and children in 1993.",ALLERGIC RHINITIS AR,ATOPIC DISEASE
502912802,7/14/2014 12:46:56,,1322812601,7/14/2014 12:46:45,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],infections.,da,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 12:49:05,,1322814063,7/14/2014 12:48:42,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],causes from exogenous,n/a,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 12:53:32,,1322817198,7/14/2014 12:53:12,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[SYMPTOM],[SYMPTOM],endogenous causes,N/A,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 13:17:29,,1322833259,7/14/2014 13:16:50,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],distinguish from,N/A,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 13:19:06,,1322834272,7/14/2014 13:18:45,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],causes,N/A,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 13:36:00,,1322846074,7/14/2014 13:35:19,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],eczema,N/A,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 13:40:10,,1322849188,7/14/2014 13:39:42,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[OTHER],[OTHER],endogenous exogenous,N/A,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 13:43:33,,1322851628,7/14/2014 13:40:49,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[OTHER],[OTHER],distinguish endogenous causes from exogenous,N/A,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 13:49:07,,1322855835,7/14/2014 13:48:13,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CAUSES],[CAUSES],causes from,N/A,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 13:52:08,,1322858018,7/14/2014 13:51:35,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],ATOPY) ALLERGIC DERMATITIS),n/a,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 13:56:39,,1322861077,7/14/2014 13:56:23,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],causes,Na,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 14:06:10,,1322867593,7/14/2014 14:05:35,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],causes from exogenous,na,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 14:10:51,,1322870572,7/14/2014 14:10:11,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],distinguish from,Opposites,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 14:34:05,,1322886961,7/14/2014 14:33:58,instagc,1.0,27753923,GBR,"","",188.30.192.65,[TREATS],[TREATS],to distinguish,n/a,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912802,7/14/2014 14:41:54,,1322892280,7/14/2014 14:40:45,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],causes from exogenous,N/A,122,71,140,76,-1,RO-cause_of,900276-FS1,"The pattern of eczema can help to distinguish endogenous (dyshidrosis, ATOPY) causes from exogenous (contact irritant and ALLERGIC DERMATITIS) and the common differential diagnoses (psoriasis, fungus infections.",ALLERGIC DERMATITIS,ATOPY
502912803,7/14/2014 12:58:51,,1322820787,7/14/2014 12:58:26,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],exacerbation of preexisting with use of,n/a,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 13:06:07,,1322825465,7/14/2014 13:05:14,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[SYMPTOM],[SYMPTOM],has occurred.,N/A,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 13:20:27,,1322835180,7/14/2014 13:20:13,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],use,N/A,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 13:40:55,,1322849730,7/14/2014 13:40:07,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],reported with use PIs;,N/A,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 13:45:10,,1322852690,7/14/2014 13:44:40,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with use,n/a,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 13:57:45,,1322861787,7/14/2014 13:55:51,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DIABETES reported with use DIABETIC KETOACIDOSIS,N/A,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 13:59:37,,1322863106,7/14/2014 13:58:59,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.,N/A,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 14:28:31,,1322882938,7/14/2014 14:28:04,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],has occurred.,N/A,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 14:29:59,,1322884086,7/14/2014 14:29:02,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],has occurred.,N/A,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 14:42:39,,1322892800,7/14/2014 14:42:20,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIABETES MELLITUS DIABETIC KETOACIDOSIS,n/a,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 14:43:44,,1322893576,7/14/2014 14:43:25,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reported with,[DIAGNOSE_BY_TEST_OR_DRUG],142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 14:51:24,,1322898128,7/14/2014 14:50:13,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],exacerbation of preexisting,N/A,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 14:58:29,,1322902617,7/14/2014 14:58:14,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],has occurred.,N/a,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 15:01:08,,1322904205,7/14/2014 15:00:29,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurred.,n/a,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912803,7/14/2014 15:02:38,,1322905061,7/14/2014 14:59:59,prodege,1.0,27934334,GBR,Q2,Wokingham,86.166.73.21,[MANIFESTATION],[MANIFESTATION],has occurred.,N/A,142,98,162,115,-1,RO-cause_of,900112-FS1,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
502912804,7/14/2014 12:49:33,,1322814354,7/14/2014 12:49:25,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],should,da,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 13:05:54,,1322825241,7/14/2014 13:05:22,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],that efforts should be made to postpone travel to,n/a,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 13:08:58,,1322827440,7/14/2014 13:08:25,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],vaccine should be used,N/A,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 13:17:35,,1322833338,7/14/2014 13:14:45,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[NONE],[NONE],N/A,"IT TALKS ABOUT THE VACCINE TO BE USED IN PREGNANCY IN RARE CASES, AND ADVISES AGAINST TRAVELING TO AREAS WITH YELLOW FEVER. NO CONNECTION TO PREGNANCY",160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 13:28:39,,1322840870,7/14/2014 13:27:34,superrewards,1.0,22551185,GBR,"","",87.113.87.199,[OTHER],[OTHER],postpone travel to YELLOW FEVER endemic areas until after delivery.,N/A,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 13:30:30,,1322842113,7/14/2014 13:29:32,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[OTHER],[OTHER],postpone travel to endemic areas,na,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 13:37:08,,1322846906,7/14/2014 13:36:18,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[NONE],[NONE],N/A,No direct relationship. One should just be careful with yellow fever vaccination if pregnant,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 13:37:53,,1322847490,7/14/2014 13:36:59,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SIDE_EFFECT],[SIDE_EFFECT],PREGNANCY YELLOW FEVER,n/a,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 13:46:57,,1322854216,7/14/2014 13:45:43,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[NONE],[NONE],N/A,It is saying if you are pregnant to not go to area where it is possible to get the sickness yellow fever,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 13:48:13,,1322855168,7/14/2014 13:46:04,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[LOCATION],[LOCATION],during PREGNANCY in rare circumstances efforts should be made to postpone travel to YELLOW FEVER areas until after delivery.,N/A,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 13:48:14,,1322855181,7/14/2014 13:47:17,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",rare circumstances,n/a,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 13:55:58,,1322860662,7/14/2014 13:55:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[IS_A],[IS_A],postpone travel,Na,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 13:56:31,,1322861019,7/14/2014 13:55:51,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],rare circumstances,na,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 14:17:41,,1322875189,7/14/2014 14:17:31,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],PREGNANCY,N/A,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912804,7/14/2014 14:24:01,,1322879608,7/14/2014 14:21:45,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],during PREGNANCY postpone travel endemic areas,N/A,160,74,171,83,1,RO-contraindicated_drug,901169-FS1,"106 ,   b   Advise such women that the vaccine should only be used during PREGNANCY in rare circumstances and that efforts should be made to postpone travel to YELLOW FEVER endemic areas until after delivery.",YELLOW FEVER,PREGNANCY
502912805,7/14/2014 12:57:49,,1322820022,7/14/2014 12:56:57,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],normal follow up cervical scrapes with SEVERE DYSPLASIA and,n/a,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 12:59:14,,1322821009,7/14/2014 12:57:51,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[OTHER],[OTHER],and,N/A,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 13:01:07,,1322822201,7/14/2014 13:00:25,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[MANIFESTATION],[MANIFESTATION],HPV was detected in scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU,N/A,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 13:03:05,,1322823560,7/14/2014 13:02:45,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 13:09:23,,1322827767,7/14/2014 13:08:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was detected,N/A,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 13:22:39,,1322836878,7/14/2014 13:22:22,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 13:34:07,,1322844719,7/14/2014 13:33:39,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 13:42:49,,1322851064,7/14/2014 13:42:19,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[NONE],[NONE],N/A,There just part of a list,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 13:46:03,,1322853401,7/14/2014 13:44:27,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HPV DNA was detected in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU,N/A,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 13:53:44,,1322859092,7/14/2014 13:52:44,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 13:54:12,,1322859462,7/14/2014 13:53:57,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 13:55:54,,1322860570,7/14/2014 13:55:31,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],scrapes with,n/a,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 14:02:45,,1322865331,7/14/2014 14:02:12,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SIDE_EFFECT] [ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]",with,na,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 14:05:29,,1322867057,7/14/2014 14:05:00,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[CAUSES],[CAUSES],SEVERE DYSPLASIA and CARCINOMA IN SITU,N/A,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912805,7/14/2014 14:17:07,,1322874844,7/14/2014 14:16:00,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with SEVERE DYSPLASIA and CARCINOMA IN SITU,N/A,334,355,349,372,-1,RO-disease_has_finding,901566-FS1,"HPV DNA was detected in 38% of normal follow up cervical scrapes, 51% of scrapes with atypical squamous cells of undetermined significance, 78% of scrapes with mild dysplasia (low grade squamous intraepithelial lesions), 86% of scrapes with moderate dysplasia (high grade squamous intraepithelial lesions), and in 88% of scrapes with SEVERE DYSPLASIA and CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502912806,7/14/2014 12:51:33,,1322815777,7/14/2014 12:50:48,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosing suspected,n/a,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 12:54:00,,1322817566,7/14/2014 12:53:26,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],when other topical antibiotics is suspected.,n/a,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 12:57:03,,1322819516,7/14/2014 12:56:44,prodege,1.0,11616695,GBR,P7,Wigan,92.29.199.166,[MANIFESTATION],[MANIFESTATION],diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY is suspected.,N/A,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 12:57:49,,1322820025,7/14/2014 12:56:28,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[PART_OF],[PART_OF],when,N/A,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 13:07:45,,1322826612,7/14/2014 13:07:11,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],is suspected.,N/A,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 13:20:51,,1322835423,7/14/2014 13:20:28,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[CAUSES],[CAUSES],suspected.,N/A,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 13:26:52,,1322839690,7/14/2014 13:25:48,clixsense,1.0,15189335,GBR,K3,Peterborough,81.156.166.189,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],useful in diagnosing suspected,na,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 13:32:56,,1322843897,7/14/2014 13:32:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],when,N/A,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 13:33:51,,1322844494,7/14/2014 13:32:14,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[NONE],[NONE],N/A,it just explains a test that can be used for the case when hypersensitivity is suspected. there is no direct relationship.,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 13:44:27,,1322852296,7/14/2014 13:42:59,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],a Patch testing may useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS HYPERSENSITIVITY suspected.,N/A,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 13:51:26,,1322857452,7/14/2014 13:51:01,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],when,N/A,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 13:55:13,,1322860113,7/14/2014 13:54:44,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],when,na,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 14:39:18,,1322890545,7/14/2014 14:38:57,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ALLERGIC CONTACT DERMATITIS HYPERSENSITIVITY,n/a,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 14:42:26,,1322892690,7/14/2014 14:42:00,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],when HYPERSENSITIVITY to other topical antibiotics is suspected.,N/A,91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912806,7/14/2014 14:45:04,,1322894408,7/14/2014 14:44:40,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],may be useful in diagnosing,[DIAGNOSE_BY_TEST_OR_DRUG],91,124,117,140,-1,RO-cause_of,900279-FS1,"a  Patch testing (e.g., 1% bacitracin in petrolatum) may be useful in diagnosing suspected ALLERGIC CONTACT DERMATITIS when HYPERSENSITIVITY to other topical antibiotics (e.g., neomycin) is suspected.",ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY
502912807,7/14/2014 13:14:44,,1322831350,7/14/2014 13:12:50,elite,1.0,27433978,AUS,05,Plympton,110.174.120.88,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet,N/A,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 13:23:26,,1322837503,7/14/2014 13:23:10,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],treated with a,N/A,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 13:35:38,,1322845803,7/14/2014 13:34:43,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],treated with a,N/A,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 13:54:05,,1322859289,7/14/2014 13:53:34,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],COELIAC DISEASE GLUTEN FREE DIET,n/a,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 13:59:55,,1322863291,7/14/2014 13:59:35,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,[CAUSES],[CAUSES],treated,n/a,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 14:02:48,,1322865357,7/14/2014 14:02:35,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],treated,Na,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 14:06:43,,1322867951,7/14/2014 14:06:11,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[TREATS],[TREATS],treated with a,na,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 14:15:54,,1322874077,7/14/2014 14:15:47,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],the,N/A,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 14:24:21,,1322879802,7/14/2014 14:24:02,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],treated with,N/A,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 14:33:11,,1322886429,7/14/2014 14:33:04,instagc,1.0,27753923,GBR,"","",188.30.192.65,[PREVENTS] [DIAGNOSE_BY_TEST_OR_DRUG],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]",COELIAC DISEASE,n/a,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 14:37:11,,1322889105,7/14/2014 14:35:28,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],treated with a,N/A,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 14:40:28,,1322891380,7/14/2014 14:40:08,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,[TREATS],[TREATS],treated with,[TREATS],262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 14:44:17,,1322893935,7/14/2014 14:43:50,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[TREATS],[TREATS],COELIAC DISEASE GLUTEN FREE DIET,n/a,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 14:47:11,,1322895727,7/14/2014 14:46:35,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],treated with,N/A,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912807,7/14/2014 14:57:34,,1322902038,7/14/2014 14:57:13,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],treated with a,N/a,262,231,277,246,-1,RO-has_causative_agent,903747-FS1,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
502912808,7/14/2014 12:42:11,,1322809534,7/14/2014 12:41:36,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],should be given during childhood,n/a,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 12:47:16,,1322812857,7/14/2014 12:47:07,neodev,1.0,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],POLIOMYELITIS:,da,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 13:04:41,,1322824503,7/14/2014 13:04:05,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],should be given during childhood and produces immunity,N/A,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 13:24:27,,1322838072,7/14/2014 13:23:39,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,[PREVENTS],[PREVENTS],VACCINE,na,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 13:29:19,,1322841273,7/14/2014 13:28:41,superrewards,1,22551185,GBR,"","",87.113.87.199,[TREATS],[TREATS],TRIVALENT INACTIVATED POLIOVIRUS VACCINE produces immunity,N/A,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 13:30:06,,1322841856,7/14/2014 13:29:27,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[PREVENTS],[PREVENTS],given during childhood and produces immunity,N/A,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 13:35:42,,1322845877,7/14/2014 13:34:21,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[TREATS],[TREATS],for all children POLIOMYELITIS: TRIVALENT INACTIVATED POLIOVIRUS VACCINE of should be given during childhood,N/A,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 13:38:22,,1322847790,7/14/2014 13:37:48,gifthulk,1.0,22144176,GBR,U8,Edinburgh,129.215.149.97,[OTHER],[OTHER],primary series of,N/A,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 13:49:38,,1322856161,7/14/2014 13:48:15,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],primary series of,n/a,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 13:57:27,,1322861592,7/14/2014 13:56:51,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],POLIOMYELITIS: TRIVALENT INACTIVATED POLIOVIRUS VACCINE,n/a,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 14:04:30,,1322866468,7/14/2014 14:04:14,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[PREVENTS],[PREVENTS],primary immunity,Na,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 14:08:20,,1322869008,7/14/2014 14:08:06,clixsense,1.0,25402344,CAN,ON,Wawa,24.109.124.45,[MANIFESTATION],[MANIFESTATION],POLIOMYELITIS: TRIVALENT INACTIVATED POLIOVIRUS VACCINE,N/A,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 14:11:46,,1322871109,7/14/2014 14:11:07,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],should be given,N/A,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 14:15:17,,1322873634,7/14/2014 14:15:02,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SIDE_EFFECT],[SIDE_EFFECT],poliovirus,N/A,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
502912808,7/14/2014 14:34:55,,1322887488,7/14/2014 14:34:47,instagc,1.0,27753923,GBR,"","",188.30.192.65,[MANIFESTATION],[MANIFESTATION],should be,n/a,72,36,116,49,-1,RO-has_causative_agent,903549-FS1,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
